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Cellular therapies hold great potential to treat a variety of medical conditions.  Product 
characterization of cellular therapies is particularly difficult, as they pose regulatory challenges 
due to donor heterogeneity and a lack of standard lot release tests that can reliably predict in vivo 
outcomes.  In particular, multipotent stromal cells, also called mesenchymal stem cells (MSCs), 
are potentially valuable as a cellular therapy due to their regenerative capacity and 
immunosuppressive function. Due to the required expansion and inherent heterogeneity of 
MSCs, quantitative approaches capable of measuring differentiation capacity and 
immunosuppressive function between donors and passages on a per cell basis are needed.  To 
address this unmet need, a sample set of human MSCs comprised of eight donors was created, 
cultured to early and late passages, and novel quantitative bioassays were established capable of 
measuring adipogenic and osteogenic differentiation on a per cell basis, as well as an in vitro 
assay to measure immunosuppressive function.  Based on existing bioassays, MSCs demonstrate 
a decrease in overall proliferative potential and colony forming unit capacity, while expression of 
hallmark MSC surface markers remain unchanged.  Utilizing automated microscopy techniques, 
adipogenic and osteogenic differentiation potential was quantified on a per cell basis, allowing us 
to directly assess the role of donor variability and in vitro culture on MSC function.  Overall, 
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donor variability and a decrease in differentiation potential with passage was demonstrated based 
on these quantitative assays.  Since culture-expanded MSCs increase in cell size, this parameter 
was utilized to enrich for small cells, which demonstrated that the small cell population is more 
stem-like based on these applied quantitative bioassays.  Lastly, immunosuppressive function of 
human MSCs on murine-derived clonal T cells was assessed utilizing a novel in vitro xenogeneic 
model system.  Human MSCs can inhibit murine T cell activation, rendering this an ideal system 
to assess immunosuppressive function of MSCs in vitro.  In conclusion, novel methods were 
established to quantify MSC function, and these findings were correlated with other previously-
established quantitative bioassays to better understand the role of donor variability and passaging 
on MSC potency.  Taken together, these quantitative approaches provide valuable tools to 
measure MSC quality, and supports continued efforts to improve characterization strategies for 
cellular therapies. 
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1.0  BACKGROUND 
Stem cell therapy holds great therapeutic potential to address a range of unmet medical needs.  
Adult stem cells include bone marrow stromal cells, or mesenchymal stem cells (MSCs), and are 
of great interest for their potential clinical use as cellular therapies to treat many diseases based 
on their innate reparative and immunosuppressive functions.  There are currently over 300 trials 
underway using MSCs to treat a variety of clinical conditions, including Crohn’s disease, heart 
failure, osteoarthritis, osteogenesis imperfecta, multiple sclerosis and several others (1).  MSCs 
are particularly promising as they are free of ethical concerns typically associated with 
embryonic stem cells, would not be expected to form teratomas, and are immune-privileged.   
The use of biologic therapies such as MSCs provides a unique challenge.  While drugs 
are well characterized and provide an established mode of action, biologics and cell therapies in 
general are less understood.  MSCs may come from either an autologous or allogeneic cell 
source, which means cells can come from several donors.  Cells derived from different donors 
may vary in their potency, or their ability to carry out a desired function.  Further, their potency 
may also decline due to the often required cell expansion before treatment.  Taken together, this 
establishes a need to develop assays that are capable of identifying potency based on the ability 
of MSCs to repair and immunosuppress.   
 This section will focus on the basic biology of MSCs and the underlying molecular 
mechanisms involving differentiation and immunosuppression.  An understanding of the 
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biological processes behind differentiation capacity and immunosuppression will enhance our 
ability to establish bioassays capable of measuring potency in MSCs based on donor differences 
and in vitro culturing. 
 
1.1 BASIC BIOLOGY OF MSCS 
1.1.1 MSC niche 
The idea of a stem cell niche was first described in the late 1970s by Schofield, and is described 
as the microenvironment in which stem cells are retained in their naïve state through the 
influence of local cytokines, growth factors and extracellular matrix by which they are 
surrounded (2).    
 The bone marrow is a dynamic tissue comprised of the stroma and stromal cells, whose 
primary function in vivo is to support hematopoiesis and bone formation through the secretion of 
extracellular matrix components and various cytokines and growth factors.  The bone marrow 
provides support for hematopoiesis through cell signaling that drives lineage commitment and 
differentiation of hematopoietic stem cells (3-5).  The MSCs are presumed to be the stromal cells 
that reside in the bone marrow, and were first discovered by Friedenstein, who described these 
stromal cells as adherent, clonogenic populations that are capable of self-renewal and 
differentiation (6).  The self-renewal capacity of MSCs that promote maintenance of the 
undifferentiated state involves various cytokines and growth factors, including leukemia 
inhibitory factor (LIF) (7,8) and fibroblast growth factor (FGF) (9,10).  Likewise, it has also 
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been suggested that Wnt signaling may be involved in maintenance and self-renewal in MSCs 
(11,12).   
 MSCs are typically isolated by density gradient centrifugation from a bone marrow 
aspirate.  Once placed in culture, adherent cells persist as fibroblast-like cells capable of an 
initial doubling time of 12-24 hours, which is density-dependent (13).   
 While MSCs can be derived from a variety of sources, the original tissue from which they 
were derived plays a role in their ability to carry out a desired function.  MSCs may not only be 
derived from bone marrow, but from many other sources, including adipose (14-16), skeletal 
muscle (17-20), umbilical cord blood (21-24) and dental pulp (25-28).  Further, they have also 
been shown to be derived from non-mesoderm tissues, however the focus of this work will be on 
human bone-marrow derived MSCs.  
1.1.2 MSC Phenotype 
The minimum criteria as defined by the ISCT requires that MSCs be plastic adherent, capable of 
trilineage differentiation, and ≥ 95% positive for CD73, CD90 and CD105, and lack expression 
of (≤ 2%) of CD14 or CD11b, CD79a or CD19, CD34, CD45, and HLA Class II (29).  However, 
there is currently no hallmark MSC marker, and they are therefore typically assessed using a 
panel of cell surface markers.  Identification of novel markers in the future to further define a 
multipotent, stem-like phenotype will be a useful tool in characterizing MSCs. 
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1.1.2.1 Cell surface marker expression – positive markers 
CD29 is an integrin 1 or fibronectin receptor involved in cell adhesion, hemostasis, tissue repair 
and the immune response.  Loss of integrin 1 leads to disrupted cell differentiation, as it is the 
major adhesion receptor for several extracellular matrix components (30).   CD44 is a cell 
surface glycoprotein that is the receptor for hyaluronic acid.  It is involved with cell adhesion, 
migration and cell-cell interactions, while also mediating interactions with ligands including 
osteopontin, collagens and matrix metalloproteinases (31).  CD73, otherwise known as ecto 5’-
nucleotidase, is a plasma membrane protein that is associated with lymphocyte differentiation.  It 
catalyzes the dephosphorylation of extracellular nucleoside 5’ monophosphates for cell 
metabolic purposes.  Defects in the ecto 5’-nucleotidase gene may result in calcification of joints 
and arteries.  Thy-1 antigen (CD90), is a membrane glycoprotein expressed in cord blood cells, 
bone marrow and human fetal liver cells.  Expression of this surface antigen has been shown to 
correlate with highly proliferating progenitor cells (32).  CD105, otherwise known as endoglin, is 
a component of the TGF-beta receptor complex.  CD105 is a glycoprotein of the vascular 
endothelium, and has been reported to play a crucial role in embryonic angiogenesis.  CD105 has 
been shown to be expressed ovary, uterus, fibroblasts, as well as heart, muscle and stromal cells 
(33).  Vascular cell adhesion moledule-1 (VCAM1), also known as CD106, is a cell surface 
sialoglycoprotein that is expressed in cytokine-activated endothelium, and is potentially involved 
in atherosclerosis and rheumatoid arthritis, while also mediating cell adhesion and signal 
transduction (34).  Activated leukocyte adhesion molecule (ALCAM, CD166), is involved in cell 
adhesion and migration between thymic epithelial cells and CD6+ cells during T-cell 
development.  CD166 is expressed in several cell types, including activated T cells and 
monocytes, epithelial cells, fibroblasts, and neurons (35).    
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1.1.2.2 Cell surface marker expression – negative markers 
Following bone marrow aspiration and subsequent culture, MSCs exist amongst other cell types 
with a variety of expression profiles.  During expansion in vitro, it is necessary to distinguish 
between hematopoietic stem cell (HSCs) contaminants, as well as other cell types seen in the 
bone marrow (i.e. osteoblasts, osteocytes, etc.).  MSCs should be ≤ 2% positive for HSC 
markers, including CD34 (a primitive HSC marker) and CD45 (a positive marker of all 
hematopoietic cells).  MSCs should also be negative for an endothelial/HSC marker CD31, as 
well as CD117 (a marker for hematopoietic progenitors).  Further, MSCs should also not express 
CD14 (a monocyte/macrophage marker), CD79 (recognizes a membrane glycoprotein present 
on B lymphocytes), and HLA-DR (binds to MHC class II, and is present on antigen presenting 
cells).  
1.1.2.3 Cell surface marker expression – other markers 
The STRO-1+ fraction in bone marrow was previously demonstrated to contain early osteogenic 
precursors in MSCs (36).  Expression of STRO-1 has been shown to enhance CFU capacity, 
however, its expression by flow cytometry has been shown to be variable, and may be lost with 
in vitro culture (37).  More recently, CD271, otherwise known as nerve growth factor receptor 
(NGFR), has been shown to be expressed in a small population of MSCs.  Buhring et al. 
previously demonstrated that the CD271bright population contained the CFU-forming cell 
population (38).  Further, the CD271 positive population was also shown to express higher levels 
of Wnt-related genes (39). 
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1.1.3 Trilineage differentiation capacity 
MSCs are capable of trilineage differentiation, and therefore have potential clinical applicability 
related to regenerative therapies.  MSCs can be easily differentiated in vitro provided they are 
cultured in the appropriate environment. Interestingly, MSCs have now been shown to 
differentiate to tissue types outside the mesoderm, including hepatic and neural lineages (16,40-
45).  For the purpose of this work, we will focus only on mesoderm-specific lineage pathways, 
including adipogenic, osteogenic and chondrogenic differentiation potential.     
1.1.3.1 Adipogenesis 
Adipogenesis is the process by which an MSC undergoes differentiation to a mature adipocyte.  
MSCs can be induced in vitro through the addition of exogenous factors to the culture media, 
including isobutyl methyl xanthine (IBMX), indomethacin and insulin (46).   The presence of 
IBMX, a phosphodiesterase inhibitor, blocks the conversion of cAMP to 5’AMP, which leads to 
upregulation of protein kinase A (PKA), and in turn increasing expression of hormone sensitive 
lipase (HSL).  Triacylglycerides are converted to glycerol and ultimately free fatty acids through 
the effect of HSL.  Indomethacin is an anti-inflammatory drug that promotes adipogenesis 
through peroxisome proliferator-activated receptor gamma (PPAR) (47).  Insulin promotes 
adipogenesis through binding insulin-like growth factor 1 (IGF-1), resulting in phosphorylation 
of cAMP response element–binding protein (CREB) through phosphatylinositol-3 kinase (PI3K) 
and cAMP (48).  CREB is an early regulator of major players in adipogenesis, including 
CCAAT/enhancer binding protein (C/EBP) and PPAR (49). 
 MSCs undergo terminal differentiation into a mature adipocyte following growth arrest, 
and expression of mRNAs including lipoprotein lipase (LPL), which is involved in lipogenesis 
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(50).  This is followed by activation of transcriptional factors including CCAAT/enhancer 
binding protein alpha (C/EBP) and peroxisome proliferator-activated receptor gamma (PPAR)  
(51).  Other markers of adipogenesis include adipsin, a protease involved in glucose transport 
stimulation, and adiponectin, a protein in involved in insulin sensitivity regulation (52), and  
acyl-CoA synthetase short-chain family member 2 (ACSS2), which is involved in lipid synthesis 
(50).  The terminally-differentiated adipocyte adopts a lipid-laden, spherical morphology and 
expresses mature differentiation markers, including C/EBP, PPAR, adiponectin adipocyte 
protein 2 and adipsin (53). 
1.1.3.2 Osteogenesis 
A crucial role of MSCs in vivo is osteogenic differentiation and bone formation.  In vitro 
differentiation of MSCs typically involves the addition of ascorbic acid, -glycerophosphate, and 
dexamethasone to the culture media for 14-21 days.  Ascorbic acid and -glycerophosphate 
stimulate collagen type I secretion (54), while dexamethasone stimulates osteogenesis by 
inducing expression of osteogenesis-related genes, including runt-related transcription factor 2 
(Runx2) Osterix (Osx) and bone matrix proteins (55).  Runx2 is the earliest marker of 
osteogenesis, and regulates differentiation through transforming growth factor beta 1 (TGF-1) 
and bone morphogenic protein 2 (BMP2) (56,57).  Commitment to the pre-osteogenic lineage 
involves increases in proliferative capacity and morphological changes, and involves expression 
of earlier bone markers, including ALPL, type I collagen and osteopontin.  ALPL is a regulator 
of bone mineralization expressed in preosteoblasts.  -catenin, osterix and Runx2 promotes 
differentiation of preosteoblasts into immature osteoblasts that express bone matrix protein, 
osteopontin, and bone sialoprotein (58).  A fully terminally-differentiated osteoblast adopts a 
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cuboidal morphology capable of increased mineralization and protein production (59).  Osterix 
promotes differentiation of mature osteoblasts through osteocalcin expression (60), and is also 
associated with increased expression of ALPL, collagen type I and osteocalcin in the mature 
osteoblast phenotype (61,62).   
1.1.3.3 Chondrogenesis 
The regulation of articular cartilage formation through chondrogenesis is the first developmental 
step of skeletal development in mammalian organisms, and is controlled by a variety growth 
factors and signaling molecules.  Initiation of chondrogenesis is mediated through paracrine 
factors and predominantly by a transcription factor, Sox9.  Expression of N-cadherin and Sox9 is 
upregulated by paracrine factors such as FGF, TGF-, BMPs, while Wnts negatively regulate 
chondrogenesis by blocking expression of Sox9.  Sox9 positively induces other genes involved 
in chondrogenesis, namely Sox5, Sox6, and Col2A1.  L-Sox5 and Sox6 are also required for 
expression of Col2A1 and aggrecan expression, which is the most abundant proteoglycan in 
cartilage (63).   
1.1.4 MSC heterogeneity 
MSCs are a heterogeneous population of adult stem cells, both in regards to their morphology as 
well as biological function.  MSC heterogeneity can be discussed in terms of their “inter-
population” heterogeneity, or differences between different populations, sources or donors, or in 
terms of “intra-population” heterogeneity, clonal heterogeneity within an individual population 
of MSCs (64).  In regards to morphological heterogeneity, MSCs in vitro co-exist as either small, 
rapidly dividing cells, termed recycling stem cells (RS cells), or large, slowly dividing mature 
  9 
cells (mMSCs).  Changes in biological function in MSCs may be closely tied to this 
morphological heterogeneity, and this phenomenon will be discussed more extensively in 
Chapter 4.   
1.1.5 Wnt signaling in MSCs 
Understanding signaling mechanisms underlying MSC function may allow for the identification 
of novel molecular targets to improve measurement of MSC function.  While many signaling 
pathways are involved in different aspects of MSC function, Wnt signaling may be the 
fundamental mechanism by which MSCs are capable of self renewal and differentiation.  
Specifically, canonical Wnt signaling is involved in cell fate decisions and regulating stemness in 
many stem cell types (12).   
In the presence of Wnt ligand, Wnt binds to Frizzled (Fz) and co-receptors LRP-5 and 
LRP-6, leading to the activation of cytoplasmic Disheveled (Dv1).  The presence of Disheveled 
blocks phosphorylation of -catenin by glycogen synthase kinase (GSK-3).  This allows 
accumulation of -catenin and subsequent nuclear translocation, where it binds to T-cell factor 
(TCF) and lymphoid enhancer factor (LEF) to regulate downstream targets. In the absence of 
Wnt, -catenin is phosphorylated by GSK-3, targeting it for ubiquitination and subsequent 
proteosomal degradation (65).  The role of Wnt signaling in differentiation will be discussed in 
greater detail in Chapter 4. 
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1.1.6 Immunosuppressive function 
MSCs may not only have a potential therapeutic effect because of their regenerative properties, 
but also due to their capacity for immunosuppression.  This immunoprivileged status has 
therefore extended their potential clinical relevancy to treat several autoimmune diseases, 
including type 1 diabetes, Crohn’s disease, multiple sclerosis, and others (66-69).  The ability of 
MSCs to escape the immune response may be in part due to their lack of HLA Class II antigens 
on the cell surface.  Mechanisms of immunomodulation include inhibition of proliferation and 
differentiation of T cells, B cells, natural killer cells and dendritic cells, however the focus of this 
work will be the effect of MSCs on T cells.  A more detailed background of the 
immunosuppressive function of MSCs will be reviewed in Chapter 5. 
  
1.2 CELLULAR THERAPIES USING MSCS AND THE REGULATORY 
PERSPECTIVE 
Adult bone marrow derived MSCs hold great therapeutic potential based on their capacity to 
differentiate, regenerate and support hematopoiesis, as well as their immunomodulatory 
functions.  Because of their immune-privileged status, they may be used both in autologous and 
allogeneic settings.  Over 300 clinical trials are underway using MSCs, and which are primarily 
centered around;. differentiation capacity toward osteogenic and chondrogenic lineages; stromal 
support in the hematopoietic microenvironment; immunomodulatory function; and  secretory 
profile of trophic factors involved in tissue regeneration (1). 
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 Cell based therapies are being actively developed as evidenced by several hundred 
Investigational New Drug (IND) applications at the Center for Biologics Evaluation and 
Research (CBER).  While these therapies have great promise to treat a wide variety of medical 
conditions, cellular therapies as a whole are so novel that product characterization is particularly 
challenging.   In general, optimal approaches to evaluate and select in-process or lot-release tests 
that are capable of predicting in vivo performance of cell-based therapies are still unknown.  At 
CBER, a consortium has been assembled to address the needs of product characterization in cell-
based therapies as it relates to MSC potency.   
 Regulatory science is defined as the science of developing tools, standards and 
approaches to assess the safety, efficacy, quality and performance of Food and Drug 
Administration (FDA)-regulated products.  CBER research priorities include improving or 
developing new methods to measure, and ideally quantify, biologic product quality, safety and 
efficacy.  Reviewers help to identify issues and set research priorities applicable to concrete 
product issues, with the goal of developing and integrating novel scientific technologies that 
could be used to improve biologics product characterization, availability, and quality.  Unlike 
academic or industry-based research institutions, the research focus at the FDA and CBER is 
unique, with a goal in identifying solutions related to product development challenges.  Key 
regulatory considerations as it relates to cellular therapies include the following:  (a) can 
biomarkers be identified that predict quality, potency and safety of stem-cell based products 
reliably? (b) by what mechanisms do stem cells function?, and (c)  what adverse effects, such as 
migration to an ectopic location, inappropriate differentiation or tumorigenicity are likely to 
occur?  And more specifically, as it relates to the field of MSC biology, our goals are also to 
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address the needs of the field, including quantitative measures of differentiation capacity on a per 
cell basis to assess stemness potential in MSCs. 
1.3 PROJECT OBJECTIVES 
The overarching goal of this project is to improve characterization of bone marrow-derived 
MSCs by determining the role of donor variability and in vitro expansion as it relates their 
differentiation potential and immunosuppressive function.  Further, we seek to correlate these 
characteristics with Wnt signaling to identify a mode of action, while also improving MSC 
function by enriching for a more biologically active MSC population.  
1.3.1 Objective #1:  To evaluate the role of donor variability and in vitro expansion on 
MSC characteristics. 
Hypothesis:  MSC characteristics, including cell size, CFU and proliferative capacity, and MSC 
cell surface marker expression will vary between donor cell lines, and physical and functional 
characteristics will change as a result of passaging.   
 
Due to the low percentage of MSCs in the bone marrow, MSCs will require in vitro expansion to 
obtain sufficient numbers for treatment in cellular therapies.  Further, this will also require cells 
from multiple donors.  Because of the inherent heterogeneity associated with an individual 
population of MSCs, as well as donor differences, there is a need to utilize existing and establish 
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novel quantitative assays to assess MSC characteristics that are predictive of MSC function in 
vivo.   
 Studies looking at different donors have been focused on understanding the role of in vivo 
(donor age) or in vitro (passaging) on MSC quality.  Decreases in proliferative capacity were 
more highly associated with passaging as opposed to donor age, which correlated with increased 
beta-galactosidase staining, a measurement of senescence.   
 Current assays to assess biological function of MSCs include colony forming units, 
proliferation capacity and flow cytometry to measure expression of cell surface markers.  In this 
chapter, we will utilize these assays and others to assess a baseline of biological function of the 
MSCs used in this thesis.  We have expanded cells from 8 male or female donors of a range of 
ages, to further examine MSC quality.  We will further-correlate these endpoints with 
differentiation capacity as discussed in the next chapter. 
 
1.3.2 Objective #2:  To establish quantitative bioassays to measure differentiation 
capacity in MSCs. 
Hypothesis:  Novel assays to measure differentiation can quantify changes in differentiation 
potential between donors and passages. 
 
MSCs are partially defined by their ability to differentiate to adipocytes, osteoblasts and 
chondrocytes in vitro.  To assess differentiation, staining is typically used to identify a 
differentiated phenotype.  While staining is sufficient, these methods are inherently qualitative, 
and do not take into account the heterogeneity associated with MSCs.  Further, these qualitative 
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assays cannot be used to assess differences between donors or as a result of passaging.  There is 
therefore a need to establish quantitative assays that are capable of detecting changes in MSC 
characteristics.   
Where applicable, we employed novel quantitative bioassays to measure differentiation 
on a per cell basis.  Adipogenesis will be measured using two methods; limiting dilution and 
automated microscopy.  Osteogenesis will be quantified by ALP staining.  Chondrogenesis will 
assessed qualitatively by the presence of sulfated glycosaminoglycans via Alcian Blue staining.  
Differentiation potential by donor and passage will be correlated with changes in gene 
expression of lineage-specific markers.   
1.3.3 Objective #3: Determination of the role of cell size and Wnt signaling in 
differentiation and senescence of MSCs using quantitative bioassays 
Hypothesis:  The small cell-size population contains more stem-like progenitors, and may 
correlate with decreased Wnt activity and senescence. 
 
The canonical Wnt signaling pathway is intrinsic to regulating stem cell function and cell fate 
decisions, and elicits various functions on many stem cell types (12,70).  Wnt signaling has 
different roles in differentiation and senescence.  Blocking signaling through the addition Wnt 
antagonists have previously demonstrated increased adipogenesis and improved proliferative 
capacity, while its effect on osteogenesis is more controversial (70-73).  Identifying the role of 
signaling mechanisms involved in MSC differentiation and senescence may allow for the 
discovery of novel therapeutic targets.   
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 MSCs are a heterogeneous population of adult stem cells that contain small, agranular 
proliferating cells and large, granular senescent cells.  Changes in cell size following in vitro 
expansion have been previously documented (74-76).  However, there has been little effort in the 
field to enrich for purified cell size populations to study them individually and elucidate the role 
of cell size in MSC function.   
 To better understand the role of passaging, and to correlate noted changes in cell size, we 
separated MSCs by size to apply quantitative assays to measure changes in size-associated 
biological function.  To further elucidate a mode of action, we evaluated the role of Wnt 
signaling by adding specific pathway stimuli to unsorted MSC populations.   
1.3.4 Objective #4:  To measure immunosuppressive activity in MSCs in vitro 
 
Hypothesis:  Human MSCs will exert an immunosuppressive effect on mouse T cells in a novel 
in vitro assay system. 
MSCs possess the ability to immunosuppress, and therefore there is ongoing interest in exploring 
their therapeutic potential in treating immune disorders such as Graft versus Host Disease 
(GvHD), Crohn’s Disease, multiple sclerosis and type II diabetes.  Their immune-privileged 
status is due to, at least in part, their lack of major histocompatibility complex II (MHC-II), as 
well as paracrine effects that inhibit secretion of pro-inflammatory cytokines, allowing them to 
evade the immune response.  This allows for MSCs to be used allogeneically based on this 
immunosuppressive function, and therefore can be expanded in large volumes to treat a variety 
of diseases.  Further, MSCs may therefore be expanded from multiple donors for cellular therapy 
trials. There is therefore a need to establish quantitative in vitro bioassays to assess 
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immunosuppressive function that are predictive of in vivo outcomes to determine the role of 
donor and passage differences.   
In this chapter, we will utilize a novel in vitro xenogeneic model system to assess 
immunosuppressive capacity of human MSCs on mouse T cells.  Immunosuppression will be 
measured by reduced expression of inflammatory and activation markers such as CD25, CD62L 
and CD69 by flow cytometry.  Secretion of pro-inflammatory cytokines TNF- and IFN- will 
be assessed by cytokine arrays, and expression of activation markers Tbet and GATA3 will be 
assessed by digital droplet PCR.   
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2.0  EVALUATION OF MSC CHARACTERISTICS BASED ON DONOR 
VARIABILITY AND IN VITRO CULTURING 
2.1 INTRODUCTION 
MSCs have proven to be easy to expand and differentiate in culture. MSCs are characterized by 
their adherent properties, expression of several surface antigens including CD73, CD105 and 
CD90, and tri-lineage differentiation capacity (29); however, investigators are continually trying 
to improve characterization due to MSC heterogeneity. Within a population of MSCs, variability 
in cell properties such as proliferation, morphology, differentiation capacity and cell surface 
marker expression profiles have been widely observed (77). These “intra-population” MSC 
heterogeneities and their innate plasticity may arise due to the in vivo microenvironment or also 
due to long-term in vitro culture (64).  It is this heterogeneous nature of MSCs that may allow 
them to respond effectively to a wide variety of cues in their local microenvironment to carry out 
a particular biological function.     
As these cells are extensively being tested for clinical applications, it would be useful to 
develop new quantitative bioassays to measure donor variability and the effect of passaging.  
Such tools could help to determine the suitability of a particular population of MSCs in treating a 
particular disease.  Further, these quantitative tools could be used to assess differences in 
parameters such as cell source (fat, bone marrow, muscle), cell selection for enrichment (STRO-
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1, CD271), culture media, cell density, and the effects of different protocols for expansion of 
MSCs.  Finally, these tools could enhance our understanding of MSC heterogeneity.  As stated 
by Wagner and Ho (77), there is an urgent need for more precise cellular and molecular markers 
to define subsets of MSCs.       
 In this chapter, we utilize several existing quantitative bioassays to measure differences 
in donors and passage number in a systematic fashion in order to establish a baseline of 
biological activity for the cell lines used in this thesis.  The overall goal in this chapter is to 
employ quantitative measurements that will improve characterization MSCs by determining the 
role of donor variability and passage number as it relates to the biological properties of MSCs in 
vitro. 
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2.2 MATERIALS AND METHODS 
2.2.1 Expansion of MSCs 
 
Human bone marrow-derived MSCs from 8 different donors were purchased from either All 
Cells (Emeryville, California) (PCBM1641, PCBM1632, PCBM1662, PCBM1655) or Lonza 
(Walkersville, MD) (167696, 110877, 8F3560, 127756) at passage 1 (see Table 2.1 for donor 
specifications).  MSCs were plated in T175 flasks (Cellstar) at a cell density of 60 cells/cm2, and 
expanded in complete medium containing -MEM, l-glutamine, penicillin-streptomycin 
(Invitrogen), and 16.5% lot-selected fetal bovine serum (FBS, JM Bioscience) at 37°C and 5% 
CO2.  All cell lines were expanded and cryopreserved in the same serum-selected media with 
uniform handling throughout culture, as outlined in Lo Surdo and Bauer (74). 
Table 2-1.  Summary of cell line specifications. 
 
 
 
 
MSCs from each donor were thawed and cultured at passage 1. When the cultures 
reached 80% confluence, cells were removed by trypsin (0.25% Trypsin/EDTA, Invitrogen) and 
replated into flasks at passage 2.  Once passage 2 cells became 80% confluent, MSCs were 
trypsinized, and the resulting passage 3 cells were cryopreserved in freezing medium containing 
30% FBS (JM Bioscience), 5% dimethyl sulfoxide (Sigma-Aldrich), 1% l-glutamine, and 1% 
penicillin (100 units/ml) and streptomycin (100ug/ml; Invitrogen).    An aliquot of cells was 
Designation PCBM1632 110877 167696 PCBM1641 PCBM1662 8F3560 127756 PCBM1655 
Gender M M F F F F M F 
Age 24 22 22 23 31 24 43 47 
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removed prior to cryopreservation to allow for continuous expansion to passages 3 (P3), 5 (P5) 
and 7 (P7) without any freezing in between.  Therefore, once MSCs were expanded to a 
particular passage, they were only frozen one time; at that passage.  Each passage is considered 
to be the number of times the cells were trypsinized up until cryopreservation.  The time to reach 
80% confluence varied between cell lines and passages, and is outlined in the results section in 
Table 2.2. 
 
2.2.2 Authentication of cell lines by STR profiling 
MSCs were thawed at P3, cultured until 80% confluent, then trypsinized, counted, and 
resuspended in PBS at 1 x 106 cells/ml.  20l of cell suspension was spotted on FTA sample 
collection cards and were allowed to dry.  Sample collection cards were submitted to ATCC for 
their STR-based Cell Authentication Testing Service.  As per the methodology provided by 
ATCC, seventeen short tandem repeat (STR) loci, including the gender determining loci 
Amelogenin, were amplified using commercially available Powerplex 18D Kit from Promega.  
Cell line samples were processed using the ABI Prism 3500xl Genetic Analyzer, and data was 
analyzed using GeneMapper IDX v3.1 software from Applied Biosystems with suitable positive 
and negative controls.   
2.2.3 Cell proliferation 
MSCs from all donors at P3, P5 and P7 were plated at 1000 cells/cm2 in 24-well plates 
(Corning).  Following cell adhesion, cells were placed in an Incucyte Live Cell Imager (Essen 
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Bioscience).  Nine images per well were taken every 3-4 hours.  Percent confluence 
measurements were averaged for each well (n=9) and then at each passage (n=4) and plotted as a 
function of time to measure proliferation capacity.   
2.2.4 Flow cytometry 
MSCs were thawed and cultured to 80% confluence, trypsinized and resuspended in FACS 
buffer containing 1% FBS and 0.2% sodium azide in 1X PBS.  Cells were incubated with 2.4G2 
antibody (ATCC) at 4°C for 30 minutes to block non-specific binding.  Cells were then labeled 
with the following at 4°C for 30 min:  Positive MSC markers: anti-CD29-PE-Cy5, anti-CD44-
APC, anti-CD73-PE-Cy7, anti-CD90-FITC, anti-CD166-PE (BD Pharmingen), anti-CD105-PE 
(Beckman Coulter). Negative MSC markers: anti-CD14-Alexa Fluor 488, anti-CD34-PE, anti-
CD45-PE, HLA-DR-FITC (BD Pharmingen), anti-CD79-PE-Cy5, anti-CD117-APC (Beckman 
Coulter).  Flow cytometry data was recorded using the FACS Canto II (BD Biosciences), and 
analysis was completed using Flow Jo Analysis Software.  Forward (FSC) and side scatter (SSC) 
data was recorded and analyzed to determine changes in cell size and granularity, and percent 
positive cells was measured for all markers mentioned above.   
2.2.5 Cell size measurements 
Following trypsinization, an aliquot of cells from 5 to 13 pooled T175 flasks (from one cell line 
and one passage) were counted using an automated cell counter (Nexcelom Cellometer).  MSCs 
were diluted 1:1 in trypan blue, and MSCs from each donor were cyropreserved at P3, P5 and P7 
at 1x106 cells/ml/vial.  Cell lines 127756 and PCBM1655 could not be expanded past P5 and P3 
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respectively.  The Cellometer measures the pixel area of the cells, converts that measurement to 
a surface area, and calculates a cell diameter based on the assumption that the cells are circular 
within user-defined parameters.    The minimum and maximum size range was determined, and 
the frequency of cell sizes falling within a 1m diameter bin was calculated and graphed to 
determine the size distribution of each donor and passage number. 
2.2.6 Colony forming units 
MSCs for all donors and passages were plated at 100 cells/dish in 10-cm dishes (BD Falcon) in 
triplicate for all cell lines and passages.  Cells were cultured for 14 days at 37°C and 5% CO2 
with no media changes.  At day 14, plates were washed with PBS, and stained with 3% Crystal 
Violet (Sigma-Aldrich) in 100% methanol for 10 minutes at room temperature.  Plates were 
rinsed with tap water until clear and allowed to dry.  Colonies that were greater than 2mm in 
diameter were counted, and the percent CFUs was reported per 100 cells seeded. 
2.2.7 Statistical analyses 
Statistical analyses for percent CFU data were completed using GraphPad Prism 5.  Data was 
grouped for comparisons between cell lines and between passages.  For colony forming unit 
quantification (n=3), two-way ANOVA was preformed with a Bonferroni post-hoc analysis.  
CFU data was expressed as the mean ± standard deviation.  Statistical analyses for average cell 
diameter measurements (n≥6) were completed in IBM SPSS using one-way ANOVA followed 
by a Bonferroni post-hoc analysis to assess differences within cell lines relative to P3.  Average 
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cell diameter data was expressed as the mean ± standard error of the mean. P-values < 0.05 were 
considered significant.    
2.3 RESULTS 
2.3.1 STR profiling 
For all donors, the submitted sample profile is human, and does not match any profile in the 
ATCC 8-loci STR database, indicating each sample is unique. 
2.3.2 Expansion potential of MSCs 
MSCs were cultured from donors varying in age by up to 25 years (Table 2.1), and were 
expanded to 80% confluence under identical growth conditions to ensure continuity between cell 
lines and passages.  We observed interesting differences in growth potential between different 
cell lines and passages (Table 2.2).  The overall proliferative capacity of MSCs from 127756 (43 
y/o) and PCBM1655 (47 y/o) was limited, as they were not capable of expansion beyond passage 
5 and passage 3 respectively.  However, PCBM1632 (24 y/o) shows limited growth potential by 
passage 7, requiring 17 days to become 80% confluent.  Other cell lines show a general trend 
toward increasing in time required to reach 80% confluence with increasing passage.   
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Table 2-2.  Number of days to 80% confluence during expansion. 
 
 
 
 
 
 
 
 
 
2.3.3 MSC proliferative potential decreases due to passaging and varies between donors 
MSCs were plated at identical densities to measure proliferation potential in normal expansion 
medium using a live cell imager, and percent confluence was measured as a function of time.  
MSCs decrease in proliferative potential in all donors (where applicable) by P7.  Cell lines which 
were not capable of expansion past P5 (127756) and P3 (PCBM1655) revealed decreased 
potential when compared to other donors which were expanded to P7.  Cell line 8F3560 
demonstrated the smallest change in proliferation with passage, while PCBM1632 and 167696 
revealed a substantial drop in proliferation capacity by P7 (Figure 2-1A).  The confluence at the 
4-day (96-hr) time point (Figure 2-1B) from the same dataset further demonstrates the decrease 
in proliferation potential with passage, and the variability seen between donors.   
 P2 to P3 P4 to P5 P6 to P7 
PCBM1632 7 9 17 
110877 8 9 10 
167696 8 10 12 
PCBM1641 7 8 8 
PCBM1662 10 9 12 
8F3560 9 10 9 
127756 9 11 n/a 
PCBM1655 14 n/a n/a 
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Figure 2-1.  Legend on following page. 
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Figure 2-1.  MSCs decrease in proliferative potential with passage and vary between donors.  MSCs were 
plated at 2000 cells/well in 24-well plates, and percent confluence was measured every 3-4 hours in a live cell 
imager.  (A) Percent confluence as function of time for all donors at P3, P5 and P7. Error bars represent standard 
deviation; n=4.  (B) Percent confluence at 4 day time point for all donors at P3, P5 and P7. 
 
2.3.4 Surface marker expression remains constant following passaging and between 
donors 
MSCs have been characterized by their positive expression profile, including but not limited to, 
CD29, CD44, CD73, CD90, CD105 and CD166.  MSCs for all cell lines and passages were 
analyzed by flow cytometry based on this set of markers, to determine any changes in expression 
as a function of donor variability or culturing.  All staining was done with the same antibodies, 
and events for all cell lines and passages were collected using the same cytometer settings.  
Gating analysis was based on unstained controls for each donor and each passage, to account for 
changes in forward and side scatter properties that are seen with increasing passage.  Averaged 
percent positive expression for all cell lines within a passage was not significantly different 
between passages.  Expression of CD44, CD73 and CD105 were consistently greater than 95% 
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positive, while expression of CD29 remained above 90%.  Slightly lower expression of CD90 
was seen in PCBM1632 at 88.9%, 91.6%, and 92.4% at P3, P5, and P7 respectively; all other cell 
lines and passages showed greater than 95% expression.  Cell line 127756 showed decreased 
expression of CD166 by passage 5 at 89.8%, however all other cell lines remained above 90% 
expression (Figure 2-2).   
 
Figure 2-2.  MSCs maintain expression of cell surface markers through passages.  MSCs were stained for 
CD29, CD44, CD73, CD90, CD105 and CD166 at P3, P5 and P7.  Gating was applied to unstained controls at each 
passage for each donor, and the percent positive was reported.  Data is grouped by passage number, and horizontal 
bars indicate the average percent positive expression of all (applicable) cell lines at that passage. Each donor is 
represented as a unique symbol and color, as seen in the figure legend.   
 
2.3.5 MSC cell size increases with increasing passage and varies between donors 
Acquisition of forward and side scatter data using flow cytometry allows for cell size (FSC) and 
granularity (SSC) parameters to be measured.  Quadrant gating was determined for P3 MSCs for 
one particular cell line, and then applied to P5 and P7 for that same cell line; therefore, each cell 
line has its own individual P3 gate.  The percent positive cells with high forward and side scatter 
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in the upper right quadrant (URQ) was recorded, and plotted as seen in Figure 2-3 (n=1).  An 
example of the FSC/SSC gating can be seen for cell line 167696 at P3 (left), P5 (center) and P7 
(right) in Figure 2-3B.  Most cell lines showed a trend toward increasing in FSC and SSC with 
increasing passage.  Both 127756 and PCBM1655 (oldest donors) showed a higher percentage 
(11.2 and 17% respectively) at P3 then the other cell lines.  8F3560 remained at a relatively 
stable value, varying between 8.4% (P3), 10.1% (P5) and 9.7% (P7). 
 
 
Figure 2-3. MSCs increase in forward and side scatter with increasing passage.  (A) FSC/SSC quadrant gating 
was applied to each individual dot plot at P3.  The P3 gates were applied to P5 and P7 for each particular cell line.  
Changes in percent positive cells in the Upper Right Quadrant (URQ) were recorded, plotted, and grouped by cell 
line; n=1. Purple bar = P3; orange bar = P5; green bar = P7. (B) Example of quadrant gating analysis on FSC/SSC 
dot plots from donor 167696 at P3 (left), P5 (center) and P7 (right).  Percent positive in URQ is shown in the red 
dashed line following gating analysis. 
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Changes in cell size were also measured using a Cellometer, which measures the area of 
the cells in pixels, converts this measurement to a cell diameter, and then calculates the cell 
diameter assuming the cells are circular, as described in the methods.  During expansion of each 
cell line, cell numbers and diameters were recorded immediately prior to cryopreservation.  As 
seen in Figure 2-4, all cell lines showed an increase in cell diameter from P3 to P7 (where 
applicable), and this increase in cell size is highly significant (p<0.01 8F3560, p<0.001 for all 
other cell lines).  The increase in cell size with increasing passage as measured by the Cellometer 
is consistent with findings in Figure 2-3 as measured by flow cytometry. 
 
Figure 2-4.  MSCs increase in cell size with increasing passage, and vary between cell lines.  Bars represent 
average cell diameter (m) counts of varying sample sizes (n≥6), as determined by Cellometer measurements. 
Statistical comparisons were made within cell lines, relative to P3.  Error bars represent standard error of the mean.  
Purple bar = P3; orange bar = P5; green bar = P7.  ***p<0.001, **p<0.01, *p<0.05. 
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2.3.6 MSC CFU capacity decreases with increasing passage and varies between donors 
Percent colony forming units (CFUs) are associated with stemness in populations of MSCs.  
Percent CFUs are highest at P3 for most cell lines, and decreased with increasing passage.  
Percent CFUs ranged from 10.7% (PCBM1655) to 45% (167696) at P3, and from 5.7% 
(PCBM1632) to 21.7% (110877) at P7.  The cell lines that could not be cultured beyond P3 
(PCBM1655) and P5 (127756) had the lowest CFU percentages at P3 at 10.7% and 19% 
respectively (Figure 2-5A).  All cell lines show a significant decrease in percent CFUs from P3 
to P7, with the exception of 8F3560, which remained fairly constant between passages (Figure 2-
5A). Statistical analyses between cell lines at P3 revealed highly significant (p<0.001) 
differences in most donor comparisons (Figure 2-5B).   
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Figure 2-5.  Percentage of Colony Forming Units (CFUs) tends to decrease with increasing passage, and 
varies between cell lines.  (A) CFUs were calculated as a percentage by quantifying the number of colonies, and 
normalizing to the number of plated cells at Day 0.  Error bars represent standard deviation; n=3.  Purple bar = P3; 
orange bar = P5; green bar = P7. Statistical comparisons were made within cell lines, relative to P3.  (B) Statistical 
analysis of CFU data for comparison between cell lines. Purple outline = P3, orange outline = P5, green outline = 
P7. For (A) and (B), ***p<0.001, **p<0.01, *p<0.05, ns = not significant, n/a = not applicable. 
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2.4 DISCUSSION 
Between populations of MSCs, variability in cellular properties such as proliferation, 
morphology, and cell surface marker expression profiles have been previously observed and 
confirm our findings here.  These differences between populations of MSCs derived from 
different donors, i.e. “inter-population heterogeneity”, can be quantified through the use of 
existing population-based bioassays that have been previously used to identify and characterize 
MSCs (64). Further, these quantitative bioassays can be utilized to correlate with newly 
discovered biomarkers or other novel quantitative assays that may predict a biological function.   
Accordingly, in order to establish a complete assessment of the MSC cell line characteristics 
utilized here, cells were analyzed based on their marker expression profile and cell size, as well 
as their CFU and proliferative capacity.   The results presented in this chapter will therefore be 
discussed in Chapter 3, in the context of differentiation capacity, in order to provide a more 
complete analysis and overview of MSC properties in vitro.  
 
 
2.5 CONCLUSION 
MSCs from eight different donors of various ages were assessed for colony forming unit 
capacity, proliferation, and cell surface marker phenotype at passages 3, 5 and 7.  Following 
expansion, MSCs demonstrated a marked increase in cell size, and this was measured and 
confirmed by FSC/SSC analysis and a cellometer.  Increases in cell size correlated with 
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decreased proliferative potential and CFU capacity.  However, MSC phenotype assessment by 
flow cytometry does not reflect functional heterogeneity, which we can detect through our 
quantitative bioassays.  Therefore, while assessment of cell surface markers is important for 
identifying MSCs, it does not reflect changes in function that can be detected through other 
quantitative bioassays discussed here, as well as differentiation assays that are discussed in the 
following chapter.   
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3.0  ESTABLISHMENT OF QUANTITATIVE BASSAYS TO MEASURE 
DIFFERENTIATION CAPACITY IN MSCS 
3.1 INTRODUCTION 
MSCs are available from adult tissues, however the percentage of MSCs in the bone marrow is 
low, ranging from 0.001 – 0.01% (78). In order to obtain sufficient numbers, bone marrow MSCs 
are typically expanded substantially in tissue culture before use.  Following expansion by cell 
culture passaging, the biological properties of MSCs are often evaluated using qualitative assays 
to assess differentiation capacity. The availability of robust quantitative methods to assess 
differentiation capacity on a per cell basis in heterogeneous cell populations like MSCs would be 
of great value to assess MSC quality during and following the expansion process, and to 
determine if there are differences in the differentiation capacity of MSCs from different donors.     
Several studies have examined the role of donor differences and cell passaging on MSC 
proliferation and differentiation capacity. Stenderup et al. studied MSCs from donors grouped by 
age to determine the role of donor age and cell culture expansion on bone and fat forming 
capacity, proliferation potential, and senescence. It was observed that an increase in senescence 
in older donors which was accompanied by a decrease in overall proliferative potential. 
However, no changes were seen in adipogenic or osteogenic capacity based on donor age.  
Following cell expansion, a decrease both in adipogenic and osteogenic potential was observed. 
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(76).  Bonab et al. also demonstrated this decreased capacity for differentiation with cell 
expansion (79).   
These approaches largely disregard the cellular heterogeneity within populations of 
MSCs (72,80).  As reviewed by Pevsner-Fischer et al., intra-population heterogeneities have 
been widely observed in MSCs, and may be in part due to the in vivo microenvironment or in 
vitro expansion. The heterogeneous nature of MSCs may also allow them to efficiently respond 
to a variety of cues seen in vivo, as demonstrated by their role in differentiation, tissue 
regeneration and immunosuppression (64).  Quantitative measurements made on a per cell basis 
take into account this inherent heterogeneity observed in MSCs, and will allow for quantification 
of progenitor cells that are capable of carrying out a desired function. Further, these assays can 
be applied beyond measurement of donor- and passage-related differences, including use for 
functional analysis of populations purified by currently available cell surface markers (i.e. 
sorting for STRO-1 (36,81), CD271 (82,83), or other newly discovered biomarkers (84)), or 
various MSC sources (bone marrow, adipose tissue, muscle, placenta, umbilical cord, etc.). 
Tri-lineage differentiation potential was examined for all donors and passages using 
quantitative bioassays, where possible.  Limiting dilution was used as a technique to quantify 
adipogenic differentiation in MSCs.  Following expansion of MSCs from 2 cell lines to passages 
3, 5 and 7, it was shown that adipogenic precursors can decrease with increasing passage, and 
can vary between cell lines from different donors.  Differentiation was successfully quantified on 
a per-cell basis with this simple, quantitative assay that can be utilized in almost any laboratory 
(74).  This methodology was further expanded upon to quantify adipogenic differentiation using 
additional cell lines and a novel, automated technique to quantify differentiation following 
adipogenesis using automated microscopy.  Osteogenic differentiation was quantified by 
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measuring threshold-based surface area staining and normalizing to nuclei.  Chondrogenic 
differentiation was assessed qualitatively by Alcian Blue staining.   Changes in gene expression 
for lineage-specific markers were also examined to correlate with bioassay outcomes.  Our 
findings were correlated with previously-established quantitative assays (data shown in Chapter 
2) to better understand the role of donor variability and passaging on MSC stemness and 
differentiation capacity. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Adipogenesis 
Two different methods were applied to MSCs to quantify adipogenic precursors, including 
limiting dilution and automated microscopy methods.  Due to the labor intensive nature of the 
limiting dilution assay, this approach was applied to only 2 donors.  Automated microscopy was 
applied to all donors.   
3.2.1.1 Limiting dilution technique 
MSCs from 2 cell lines (PCBM1632 and PCBM1641) were plated at 1000, 500, 250, 125, 63 and 
32 cells/well at 48 wells/dilution in 96-well plates.  After cells were allowed to adhere for 24 
hours, expansion media was removed and 100ul/well adipogenic differentiation medium 
(NHAdipoDiff; Miltenyi Biotec) was added (day 0).  Differentiation media was supplemented 
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every 3-5 days until day 21.  At day 21, plates were removed from culture, fixed with 10% 
formalin, and stained with Oil Red O dye (Sigma-Aldrich).   
 All wells were scanned visually by eye.  Wells containing at least one differentiated cell 
(cells containing lipid droplets stained by Oil Red O) were scored positive.  Precursor 
frequencies were determined plotting the fraction of non-responding wells versus cell dilution on 
a semi-logarithmic plot.  For calculating the non-responding wells, a value of 0.0001 was plotted 
for the lowest dell dose where all wells responded.  In these instances, data for higher cell doses 
were not plotted.  This approach was used to employ only data that generate a linear dose 
response.  The inverse of the cell dose corresponding to 37% of the non-responding wells is the 
precursor frequency (85).  Figure 3-1 shows an example of how data fro this technique can be 
used to determine the frequency of adipogenic precursors in a population of MSCs. 
 
 
 
Figure 3-1.  Illustration of limiting dilution methodology to calculate precursor frequency.  (A) Cells are plated 
after serial dilution (cell dose) and are subjected to a stimulus, that is, differentiation medium.  The response at each 
dosage is quantified and the number of responding wells is determined.  (B)  The number of non-responding wells at 
each dilution is plotted on a semi-log plot as a function of cell dose, and points are best fit to a trend line.  Using the 
exponential form of the equation, the precursor frequency (x) can be calculated assuming y=0.37. 
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3.2.1.2 Automated microscopy 
For automated microscopy experiments, MSCs were thawed, cultured until 80% confluence, and 
plated in 12-well plates at 10,000 cells/well.  Following cell adherence for 24 hours, adipogenic 
differentiation medium (NH AdipoDiff, Miltenyi Biotec) was added to differentiation wells; 
undifferentiated controls were cultured in complete expansion medium.  Medium was changed 
every 3 days and cultured until Day 21.  At day 21, MSCs were fixed with 10% formalin (Sigma-
Aldrich) and stained with Nile Red dissolved in DMSO (Sigma-Aldrich) at a 5g/ml final 
concentration for 45 minutes at room temperature to visualize lipid droplet formation within 
MSCs.  Cells were washed with PBS, and nuclei were stained with 1mg/ml Hoechst dissolved in 
water (Sigma-Aldrich) for 30 seconds. 
3.2.1.3.1 Image acquisition 
Widefield fluorescence microscopy was performed on a Nikon Ti-S inverted microscope with 
the addition of a Prior automated stage, excitation and emission filter wheels, episcopic shutter, 
and remote focus attachment.  Acquisition of all datasets utilized a 10x, Plan Fluor objective, and 
Nikon Intensilight widefield illumination source.  Filtering of excitation and emission 
wavelengths for both Hoechst and Nile Red fluorophores was accomplished using the 
appropriate filters of a Sedat Quad filter set from Chroma Technology (Hoechst Excitation Filter: 
350nm peak, 50nm bandpass.  Hoechst Emission Filter:  457nm peak, 50nm bandpass.  Nile Red 
Excitation Filter:  490nm peak, 20nm bandpass.  Nile Red Emission Filter:  617nm peak, 73nm 
bandpass).  Acquisition of frames was accomplished with a Photometrics CoolSnap EZ, cooled, 
interline CCD.   Multi-dimensional acquisition (intra-well, inter-well, multi-channel, and 
autofocus) was accomplished through NIS-Elements software.  Sampling of each 12-well plate 
was employed by an acquisition routine such that each well would be imaged randomly in 25 
  39 
locations, which excluded the outer 15% of each well (to exclude edge-effects).   This randomly 
generated pattern was replicated (same locations with respect to each well) in the following wells 
to ensure that the gradient (from edge-to-center) was equally sampled in all wells and did not 
bias the resultant analysis.  Order of acquisition proceeded to ensure the accuracy of the stage 
locations (with respect to channel registration) by capturing both channels before proceeding to 
the next location, as well as focal plane, by implementing an autofocus routine at each stage 
location.  The autofocus routine utilized both Hoechst and Nile Red as reference channels, as the 
focal plane differed in each channel. 
3.2.1.3.2 Image analysis 
Image analysis was accomplished using NIS-Elements software, post-acquisition, by generating 
an analysis routine (macro) designed to automate the segmentation tools rather than performing a 
more manual, step-by-step analysis of each image.  Once generated, the macro was run across an 
entire plate’s dataset (300 images per plate) or further streamlined by running across multiple 
plates in sequence.  After each plate, the data was exported to Microsoft Excel for further data 
sorting and analysis.  The goal of the segmentation routine was to count, in an automated 
fashion, the number of total nuclei (per 10x field) as well as the number of those nuclei which 
had an associated adipocyte (positive for Nile Red).  The number of those positive for Nile Red 
could then be normalized to the number of total nuclei per image, which varied dramatically as 
the sampling location moved from edge to center.  The normalized value was averaged across the 
25 images in each well, and then averaged across 3 wells for n=3 for each donor at each passage.  
Data was plotted as the percentage of Nile Red positive cells. 
To ensure the accuracy of the generated macro, as well as demonstrate the variability of 
manually counting, an entire plate’s data set was counted manually by utilizing a taxonomy 
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count option of NIS-Elements, whereby each of 3 separate users would click each individual 
nucleus, as well as those positive for Nile Red stain, as the software tallied the numbers.  The 
manual analysis was completed for donor PCBM1632 at P3, P5 and P7.   
 
3.2.2 Osteogenesis 
MSCs from all cell lines were thawed, cultured until 80% confluence, and plated at 5000 cells 
per well in 24-well plates in normal expansion medium.  Cells were allowed to adhere for 24 
hours, then expansion medium was replaced with osteogenic differentiation medium (NH 
OsteoDiff, Miltenyi Biotec).  Media was changed every 3-4 days, and cultured for 14 days. 
3.2.2.1 ALP staining and quantification 
Following 14 days of culture, differentiated MSCs were fixed in 4% paraformaldehyde for 20 
minutes, and rinsed with PBS.  To make the ALP staining solution, 1 pellet of Fast Blue RR salt 
(Sigma Aldrich) was added to 48ml of DI water, vortexed, and allowed to sit for 10 minutes.  
ALP Napthol (Sigma Aldrich) was brought to room temperature, and 2ml was added to the 
pellet/water solution.  Staining solution was added to samples and incubated for 30 minutes at 
room temperature and washed with PBS.  Following ALP staining, samples were then stained 
with 1mg/ml Hoechst dissolved in water (Sigma-Aldrich) for 30 seconds, and imaged using both 
brightfield (ALP staining) and fluorescence (Hoechst) 
  A 5x6 grid of images at the center of the well were acquired by automated microscopy in 
both fluorescence and brightfield to assess nuclei and ALP respectively.  Positive ALP staining 
was measured via a macro designed to threshold and report pixel area of blue staining associated 
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with ALP.  A separate macro quantified the nuclei counts for the same image locations.  Binary 
area (m2) was normalized to nuclei for that image, and averaged for the 30 images acquired per 
well.  Triplicate wells were then averaged to report binary area per nucleus.   
3.2.3 Chondrogenesis 
MSCs from all cell lines were thawed, and cultured until 80% confluence.  Cells were 
trypsinized, counted, and resuspended in chondrogenic differentiation medium (NH 
ChondroDiff, Miltenyi Biotec) at 400,000 cells/ml.  500l of cell suspension was added to 15ml 
conical tubes, centrifuged at 1200rpm for 10 minutes, and cultured in pellet culture for 21 days.  
Medium was changed every 3-4 days.  At day 21, pellets were washed with PBS, fixed in 10% 
formalin for 24 hours, and submitted to American Histolabs.  Samples were paraffin embedded, 
sectioned at 5m, and stained with Alcian Blue to identify sulfated glycosaminoglycans.  Images 
were acquired on an upright Nikon microscope with a DS-Ri1 camera.  Images were taken at 
10X and 40X for all differentiated samples and undifferentiated controls.   
3.2.4 qRT-PCR 
To measure changes in gene expression following adipogenesis, cell lines from all donors at P3, 
P5, and P7 were plated at 3.75 x 105  cells per 10cm dish, and cultured in adipogenic 
differentiation medium (NH AdipoDiff, Miltenyi Biotec) for 14 days.  At day 14, differentiated 
cells were washed with PBS, and 600l of RLT lysis buffer (Qiagen) was added to each plate.  
Cell lysates were collected, snap frozen in liquid nitrogen and stored at -80°C for future RNA 
isolation. For osteogenesis, cells were plated at 1.5 x 105 cells per 10cm dish, and cultured in 
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osteogenic differentiation medium (NH OsteoDiff, Miltenyi Biotec) for 14 days.  To measure 
changes in gene expression following chondrogenesis, cell pellets were cultured as described in 
section 3.2.3 for 15 days.  At day 15, pellets were washed with PBS, and 4-5 pellets were 
combined per sample set in 600l RLT buffer.  Cells were homogenized at 20,000g for 15-20 
seconds using a Brinkmann Polytron PT 3000 homogenizer. Homogenized cell lysates were snap 
frozen and stored at -80°C for later processing. Lastly, for controls, MSCs from all cell lines and 
passages were thawed, cultured in expansion medium in a T175 flask until 80% confluence.  
Cells were trypsinized, pelleted and snap frozen for later RNA preparation.  RNA was made 
using RNeasy columns following manufacturer’s instructions (Qiagen).  Total RNA quantity was 
determined using a NanoDrop (Thermo Scientific) and RNA quality was assessed using a 
Bioanalyzer (Agilent).   
 cDNA was synthesized using the Quantiscript Reverse Transcription Kit according to 
manufacturer’s instructions (Qiagen) at 42°C for 15 minutes, followed by inactivation at 95°C 
for 3 minutes. qRT-PCR was preformed using the Taqman Gene Expression Master Mix 
(Applied Biosystems) per the manufacturer’s instructions with primer targets outlined below.  
15ng of cDNA-equivalents was added to each reaction.  The primers used were based on genes 
known to be involved in adipogenesis, osteogenesis or chondrogenesis (Table 3-1).  PCR was 
performed using an Applied Biosystems 7900: 50°C for 2 minutes; 95°C for 10 minutes; 40 
cycles of 95°C for 15 seconds and 60°C for 1 minute per cycle.  All conditions were repeated in 
triplicate with 20l per well.  Data was analyzed using SDS 2.3 software (Applied Biosystems). 
All target genes were normalized to GUSB (based on an assessment of appropriate housekeeping 
genes following differentiation).   
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Table 3-1.  List of ABI primer/probe sets used in qRT-PCR. 
Gene Symbol Gene Name Assay ID 
PPARG peroxisome proliferator-activated receptor gamma Hs01115513_m1 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha Hs00269972_s1 
FABP4 fatty acid binding protein 4 Hs01086177_m1 
RUNX2 run related transcription factor 2 Hs00231692_m1 
ALPL alkaline phosphatase Hs01029144_m1 
SPP1 osteopontin Hs00959010_m1 
SOX9 SRY (sex determining region &)-box9 Hs01001343_g1 
ACAN aggrecan Hs00153936_m1 
COL2A1 collagen type II alpha I Hs00264051_m1 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs03929097_g1 
18S 18S ribosomal RNA Hs03928990_g1 
HPRT1 hypoxanthine phosphoribosyltransferase 1 Hs01003267_m1 
GUSB glucuronidase, beta Hs00939627_m1 
TBP TATA box binding protein Hs00427620_m1 
YWHAZ 
tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
zeta polypeptide 
Hs03044281_g1 
 
3.2.5 Statistical analyses 
Statistical analyses for limiting dilution were carried out using Microsoft Excel; data was 
analyzed using two-tailed and unpaired t-tests.  Statistical analyses for percent Nile Red positive 
data and ALP quantification were completed using GraphPad Prism 5.  Data was grouped for 
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comparisons between cell lines and between passages.  For adipogenesis and osteogenesis 
quantification (n=3), two-way ANOVA was preformed with a Bonferroni post-hoc analysis.  
Percent positive Nile Red data and ALP area/nucleus data is expressed as the mean ± standard 
deviation.  For all analyses, P-values < 0.05 were considered significant.   Analyses for changes 
in gene expression relative to passage were also completed in GraphPad Prism 5 (n=3) using a 
one-way ANOVA with a Bonferroni post-hoc analysis to measure differences relative to passage 
3.   
3.3 RESULTS 
3.3.1 Adipogenic precursors decrease with increasing passage and vary between donors 
3.3.1.1 Limiting dilution 
Limiting dilution has traditionally been used in immunology to determine the frequency of cells 
that have a particular function in a mixed population (85-88).  This method was applied to stem 
cell differentiation to quantify the adipocyte precursor frequency in cell lines PCBM1632 and 
PCBM1641.  PCBM1641 responded similarly within each cell dose at P3, P5 and P7, while the 
fraction of responding wells at P7 in PCBM1632 drops greatly at all cell dilutions (Figure 3-2A).  
As noted in the methods, a value of 0.0001 was plotted for the lowest cell dose where all wells 
responded.  For example, in Figure 3-2A, P3 cell doses greater than 500 cells per well were not 
plotted in Figure 3-2B.  
The adipocyte precursor frequency for PCBM1641 was maintained at 1 in 76, 1 in 69 and 
1 in 59 cells at P3, P5 and P7 respectively (Figure 3-2B).  PCBM1632 precursor frequencies 
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were similar at P3 and P5 at 1 in 121 and 1 in 123 respectively.  However, the precursor 
frequency for PCBM1632 dropped drastically by P7, where only 1 in 2,035 cells were capable of 
differentiating into an adipocyte (P < 0.0002, P7 compared to P3 and P5).  
 
Figure 3-2.  Adipogenic precursor frequency can differ between cell lines and with passaging.  The fraction of 
responding wells is represented as a function of dose for PCBM1641 (A) or PCBM1632 (C) at P3, P5 and P7.  (B) 
and (D) show plots of the fraction of the non-responding wells as a function of cell dose on a semi-log plot for 
PCBM1641 (B) or PCBM1632 (D) at P3, P5 and P7.  The trend line equations were used to calculate the frequency 
of adipogenic precursors.  Error bars represent standard deviation; n=3.  R2 values were >0.96 for PCBM1641 and 
>0.85 for PCBM1632 at all passages.   
3.3.1.2 Automated microscopy 
3.3.1.3.1 Percent adipogenesis 
The application of automated microscopy as a high-throughput tool to quantify differentiation in 
MSCs is a novel approach in the field.  This technology was applied to measure changes in 
adipogenic differentiation potential in all cell lines and passages in MSCs.  Following staining 
for differentiated adipocytes, images were acquired for all cell lines and passages using 
automated image capture techniques.  Image acquisition for each plate (1 donor per 12-well 
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plate, 300 images total) required approximately 2 hours of imaging time. Once image sets were 
acquired for all cell lines, the macro analysis was run to quantify Nile Red positive and nuclei 
counts for each image.  Figure 3-3 shows an example of Nile Red staining (A) and the same 
image following macro detection of differentiated adipocytes in a field of undifferentiated cells 
(B).   
 
 
 
Figure 3-3.  Example of Nile Red staining and adipocyte quantification.  (A) Image of differentiated adipocytes 
following 21 days induction.  Nile Red positive staining (green) visualized as lipid vesicles indicating a 
differentiated adipocyte; nuclei staining with Hoechst (blue).  Image taken during automated imaging at 10X 
magnification.  (B) Following analysis by the macro, Nile Red positive cells were indicated with a green transparent 
overlay plus associated nuclei (orange). Nuclei not associated with Nile Red staining are shown as blue areas. As an 
example, the software detected 9 adipocytes in this image.  Further analysis would include normalization of this 
value to total number of nuclei in this image to determine a percent of differentiated cells. 
 
 
 Nile Red counts were normalized to nuclei counts in that image, averaged within one 
well and subsequently across three wells, and reported as a percentage of Nile Red positive cells.  
As seen in Figure 3-4A, adipogenic potential varies greatly between cell lines and consistently 
decreases as a result of passaging.  13.6% of MSCs from cell line PCBM1632 were capable of 
adipogenic differentiation at P3.  This is in contrast to its 2.7% Nile Red positive cells at P7, 
indicating a 5-fold drop in adipogenic potential from P3 to P7, the largest drop in potential 
among all cell lines tested.  Cell lines 127756 and PCBM1655, the cell lines that senesced by P5 
and P3 respectively, demonstrated the 2nd and 3rd highest P3 adipogenic potential at 10.3% and 
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6.8% respectively.  Donor 8F3560 had the lowest levels of percent positive Nile Red cells, where 
at all passages MSCs showed less than 1% adipogenic potential.  Except for 8F3560, all cell 
lines showed a decrease in adipogenesis with an increase in passage, when cells were available to 
analyze, which was highly significant with p≤0.001 when comparing P3 v. P7 (Figure 3-4B).  
The extent of variability between cell lines within a particular passage is seen in Figure 3-4B.  
While most donor comparisons at P3 are significant (p<0.05), MSCs converge to a low level of 
adipogenic potential by P7, as indicated by non-significant donor differences at P7 between most 
cell lines. 
 
Figure 3-4.  Legend on following page. 
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Figure 3-4. Adipogenesis can be quantified by automated microscopy, and demonstrates both donor 
variability and decreased adipogenic potential with increasing passage.  (A) Nuclei plus Nile Red objects were 
normalized by the total nuclei count per image to report a percentage of differentiated cells (% Nile Red positive) as 
a function of passage and cell line.  Purple bar = P3; orange bar = P5; green bar = P7. Error bars represent standard 
deviation; n=3.  Statistical comparisons were made within cell lines, relative to P3.  (B) Statistical analysis of 
percent adipogenesis data for comparison between cell lines. Purple outline = P3, orange outline = P5, green outline 
= P7. For (A) and (B), ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not significant, n/a = not applicable. 
 
3.3.1.3.2 Automated versus manual analysis 
To examine the accuracy of the macro in detecting Nile Red positive cells, three individual users 
manually counted the same image set used for automated quantification for cell line PCBM1632.  
Average Nile Red positive cells at each passage were averaged across the three counters, 
indicated as the manual count (n=3), and plotted with the automated count (n=1) (Figure 3-5).  
With the assumption that the manual count is the accurate representation of the data, the 
automated counts by the macro come very close at P5 (10.52% manual v. 10.53% automated) 
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and P7 (2.89% manual v. 2.68% automated), while the automated measurement at P3 is slightly 
higher in comparison to the manual count (12.55% manual v. 13.62% automatic).  These results 
indicate that the macro automated count is an accurate representation of what a user would 
identify as a differentiated adipocyte.  In addition, when considering computation time, each user 
spent, on average, greater than 8 hours of counting time to count a single plate of 300 images.  
The software’s macro required less than 4 minutes on the analysis macro employed to count a 
single plate with 92 % or greater accuracy. 
 
 
Figure 3-5.  Manual quantification of percent positive Nile Red cells is in line with automated measurements 
in cell line PCBM1632.  The number of nuclei and Nile Red positive cells were quantified manually in cell line 
PCBM1632 by 3 different users (n=3).  The same image set was used to quantify manually as was used in the 
automated macro count.  The red bars indicate the manual counts (n=3) and the blue bars indicate automated counts 
(n=1).  Data reported as mean ± standard deviation for the manual count; n=3. 
 
3.3.1.3.3 Nuclei counts 
While the objective of this work was to quantify adipogenesis, the total nuclei counts harvested 
from the data sets also provide useful information when considering the overall proliferative 
capacity in complete medium vs. expansion medium, but also as a comparison between cell lines 
and passages.  As seen in Figure 3-6, following the addition of adipogenic differentiation media 
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for 21 days, there is a decrease in proliferation compared to the corresponding passage controls 
within a particular donor, as indicated by the average nuclei count per image.  This trend is seen 
in all cell lines and passages, and indicates MSCs decrease in proliferation following adipogenic 
stimulation.  Further, this also demonstrates the decrease in the overall proliferative capacity 
with increasing passage, both following culture in normal expansion medium as well as in 
adipogenic differentiation medium.  
 
  
 
Figure 3-6.  Proliferative potential decreases with increasing passage, and decreases upon adipogenic 
stimulation.  The number of nuclei were quantified for each image, averaged across 25 images per well, then and 
averaged across 3 wells (n=3) following adipogenic stimulation.  Nuclei were averaged in 1 well (25 images/well) 
following expansion in complete medium (n=1).  The purple, orange, and green bars to the left within a cell line 
grouping indicate unstimulated controls for P3, P5 and P7 respectively, n=1.  The light purple, orange and green 
bars to the right indicate adipogenic stimulation for P3, P5 and P7 respectively.  Error bars on differentiated data 
points indicate standard deviation, n=3. 
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3.3.2 Osteogenic potential decreases with increasing passage and varies between donors 
Automated microscopy methods were applied to assess osteogenic differentiation potential in 
MSCs.  MSCs from all donors were differentiated toward the osteogenic lineage for 14 days, and 
changes in osteogenic potential were quantified by using a macro following ALP and nuclei 
staining.   
3.3.2.1 Quantification of ALP 
ALP-positive cells were quantified by thresholding during analysis by a macro, and normalized 
to the number of nuclei to report an area per nucleus, as shown in Figure 3-7.   
 
Figure 3-7.  Measurement of ALP thresholded area and nucleus counts by automated microscopy.  
Osteogenesis-induced MSCs were stained with ALP at day 14, and imaged by automated microscopy. (A) Example 
of ALP staining (B) Threshold analysis completed on same image in panel A using a macro designed to report 
binary area in m2.  Thresholded area to be included in analysis is shown in red and outlined in green (C) Example 
of Hoecshst staining for nuclei (D) Nuclei count completed by macro.  Counted nuclei seen in red and outlined in 
green. 
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  Using automated microscopy to quantify thresholded area on a per cell basis, osteogenic 
differentiation was successfully measured by ALP staining from different cell lines.  As shown 
in Figure 3-8A, cell lines from different donors vary in their osteogenic differentiation potential.  
Cell line PCBM1632 and 127756 both demonstrate the highest level of osteogenic differentiation 
potential at P3 when compared to other cell lines.  Cell line PCBM1632 demonstrated 
significantly more ALP staining (p<0.01) than other donors, except for 127756 (Figure 3-8B).  
Cell line PCBM1655 revealed approximately 230 m2/nucleus of positive ALP, which was the 
least positive area staining of all cell lines at P3.   Further, due to in vitro culture, MSCs show a 
decrease in osteogenesis.  Four out of six cell lines capable of expansion to P7 show a significant 
decrease in osteogenic potential from P3 to P7 (p<0.0001, Figure 3-8A).  Comparisons made 
between cell lines at P7 suggest MSCs become more homogeneous between donors with a 
diminished ability to respond to osteogenic stimulation, as evidenced by mostly non-statistical 
differences (Figure 3-8B).   
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Figure 3-8.  Legend on the following page. 
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Figure 3-8. Osteogenesis can be quantified by automated microscopy, and demonstrates both donor 
variability and decreased osteogenic potential with increasing passage.  MSCs were stimulated with osteogenic 
differentiation media for 14 days, stained for ALP, and quantified based on thresholded area and nuclei count 
normalization.  (A) Thresholded area was normalized to total nuclei count per image to report area of ALP staining 
per nucleus (m2/nucleus) as a function of passage and cell line.  Blue bar = P3; turquoise bar = P5; purple bar = P7. 
Error bars represent standard deviation; n=3.  Statistical comparisons were made within cell lines, relative to P3.  
(B) Statistical analysis of osteogenesis data for comparison between cell lines. Blue outline = P3, turquoise outline = 
P5, purple outline = P7. For (A) and (B), ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not significant, n/a = 
not applicable. 
 
3.3.2.2 Positive ALP staining correlates with increased proliferative potential 
As shown in Figure 3-8, measured area of positive ALP staining was normalized to nuclei to 
obtain a quantitative measurement of osteogenic differentiation on a per cell basis.  While data 
shows osteogenic differentiation capacity decreases with passage, we wanted to determine if 
decreased osteogenic potential was associated with decreased proliferative potential with 
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passage, as demonstrated in Chapter 2.  To correlate these data, the binary area fraction, a 
measure of the thresholded area relative to the total area, was plotted against the corresponding 
nuclei count.  Cell lines capable of in vitro expansion to P7 were analyzed.  As seen in Figure 3-
9, there is a high degree of correlation between the measured binary area fraction and nuclei 
count, suggesting a role of proliferative capacity in vitro in the ability to undergo osteogenic 
differentiation.   
 
Figure 3-9. ALP expression correlates with cell number.  The fraction of positive ALP staining (binary area 
fraction) and corresponding nuclei count is reported at all passages for the following cell lines: (A) PCBM1632 (B) 
110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 and (F) 8F3560.   
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3.3.2.3 Proliferative potential following osteogenic stimulation decreases with increasing 
passage 
Osteogenic stimulation typically induces proliferation in MSCs in vitro (89).  Here, proliferative 
potential was assessed following osteogenic stimulation by nuclei quantification via automated 
microscopy.  Following osteogenesis, in vitro culture still results in decreased proliferative 
potential due to passaging, as shown in Figure 3-10.  Passage 7 cells, where applicable, all show 
a highly significant decrease in proliferative potential (p<0.0001, Figure 3-10) with respect to 
passage 3.   
 
 
Figure 3-10. Proliferative potential decreases with increasing passage following osteogenic stimulation.  
Average nuclei count per image was quantified by automated microscopy following osteogenic differentiation for 14 
days.  Blue bar = P3; turquoise bar = P5; purple bar = P7. Statistical comparisons were made within cell lines, 
relative to P3.  Error bars represent standard deviation; n=3. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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3.3.3 Chondrogenic potential decreases with increasing passage and varies between 
donors 
Changes in chondrogenic differentiation capacity were assessed qualitatively by Alcian Blue 
staining following pellet culture for 21 days (Figures 3-11 to 3-18).  Most cell lines appear to 
have a greater degree of positive Alcian Blue staining at passage 3 when compared to other 
passages.  Cell lines PCBM1641 (Figure 3-14) and PCBM1655 (Figure 3-18) demonstrated 
increased levels of positive Alcian Blue staining at passage 3 compared to other cell lines, while 
167696 (Figure 3-13) and 8F3560 (Figure 3-16) appeared to have the least degree of staining.  
All undifferentiated control cell pellets stained negative for Alcian Blue. 
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Figure 3-11.  Alcian Blue staining in cell line PCBM1632 following chondrogenic differentiation.  MSCs from 
cell line PCBM1632 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either 
chondrogenic differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates 
positive staining for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 
10X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCBM1632 
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Figure 3-12.  Alcian Blue staining in cell line 110877 following chondrogenic differentiation.  MSCs from cell 
line 110877 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either chondrogenic 
differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates positive staining 
for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 10X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110877 
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Figure 3-13.  Alcian Blue staining in cell line 167696 following chondrogenic differentiation.  MSCs from cell 
line 167696 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either chondrogenic 
differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates positive staining 
for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 10X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
167696 
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Figure 3-14.  Alcian Blue staining in cell line PCBM1641 following chondrogenic differentiation.  MSCs from 
cell line PCBM1641 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either 
chondrogenic differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates 
positive staining for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 
10X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCBM1641 
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Figure 3-15.  Alcian Blue staining in cell line PCBM1662 following chondrogenic differentiation.  MSCs from 
cell line PCBM1662 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either 
chondrogenic differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates 
positive staining for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 
10X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCBM1662 
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Figure 3-16.  Alcian Blue staining in cell line 8F3560 following chondrogenic differentiation.  MSCs from cell 
line 8F3560 P3 (top), P5 (middle), and P7 (bottom) were cultured in pellet culture for 21 days in either chondrogenic 
differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates positive staining 
for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 10X. 
 
 
 
 
 
 
 
 
 
 
 
8F3560 
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Figure 3-17.  Alcian Blue staining in cell line 127756 following chondrogenic differentiation.  MSCs from cell 
line 127756 P3 (top), and P5 (bottom) were cultured in pellet culture for 21 days in either chondrogenic 
differentiation medium (chondrogenesis) or normal expansion medium (control).  Blue indicates positive staining 
for sulfated glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 10X. 
 
 
 
 
 
 
Figure 3-18.  Alcian Blue staining in cell line PCBM1655 following chondrogenic differentiation.  MSCs from 
cell line PCBM1655 P3 was cultured in pellet culture for 21 days in either chondrogenic differentiation medium 
(chondrogenesis) or normal expansion medium (control).  Blue indicates positive staining for sulfated 
glycosaminoglycans, pink indicates nuclei.  Larger images taken at 40X; insets taken at 10X. 
 
127756 
PCBM1655 
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3.3.4 MSCs differ in gene expression of lineage-specific markers following differentiation 
To better understand the molecular response to differentiation in different cell lines and passages, 
changes in gene expression were assessed following adipogenic, osteogenic, and chondrogenic 
differentiation using common lineage-specific markers.    
3.3.4.1 Determination of an appropriate housekeeping gene  
Many common reference genes are unsuitable for use by qRT-PCR due to their altered 
expression in varying growth and differentiation conditions, as a stable house-keeping gene is a 
requisite to obtain reliable results.  We found that commonly used glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and 18S ribosomal RNA (18S) demonstrate a large degree of altered 
expression following adipogenic differentiation, making them unusable for our differentiation 
studies.  The stability of additional house-keeping genes was therefore assessed, including 
TATA-binding protein (TBP), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide (YWHAZ), glucuronidase beta (GUSB) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) (90).   
Levels of mRNA transcript levels of the above-mentioned house keeping genes were 
assessed by reporting a raw Ct value following amplification.  Cell line PCBM1632 at P3 and P7 
was assessed in both undifferentiated and adipogenic-differentiated conditions (Figure 3-19).  
TBP (Ct values ranging from 30.3 to 31.8) and GUSB (29.0 – 30.1) showed the least variability 
between sample groups, while YWHAZ (23.4 – 25.2) and HPRT1 (28.7 – 30.7) varied to a 
slightly greater extent (Figure 3-19).  Because GUSB demonstrated the least variability between 
sample groups, this house-keeping gene was utilized in all qRT-PCR human MSC studies.   
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Figure 3-19.  House-keeping genes show variable expression in response to differentiation.  MSCs from cell 
line PCBM1632 P3 and P7, undifferentiated (control) and adipogenic lineage-differentiated were analyzed for 
changes in expression of house keeping genes as a result of passaging or following differentiation.  Raw Ct values 
following qRT-PCR are reported. 
 
3.3.4.2 Adipogenesis 
Changes in adipogenic gene expression were evaluated to correlate with our in vitro quantitative 
assays, as well as to assess the response of different donors and passages to adipogenic stimuli.  
Changes in adipogenesis-related genes tend toward decreasing with passage in most cell lines, 
which is in line with the automated microscopy results as shown in Figure 3-4.  Cell lines 
PCBM1632, PCBM1641, and 8F3560 show an increase in expression of C/EBP from P3 to P5 
(Figures 3-20A, 3-20D, and 3-20F respectively).   All cell lines except PCBM1641 show a 
statistically significant decrease from P3 to P7 in FABP4 expression following adipogenic 
differentiation (p<0.01, Figure 3-21).   Changes in gene expression patterns in PPAR also 
concurs with other adipogenic gene markers, showing most cell lines significantly decrease in 
expression from P3 to P7 (p<0.01, Figure 3-22) with the exception of PCBM1641 (Figure 3-
22D) and 8F3560 (Figure 3-22F).  Overall fold change in cell line 8F3560 was the smallest in all 
adipogenic markers.  A re-representation of the data as a donor comparison for all adipogenesis-
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related genes can be seen in Appendix A, Figures A-1-1 (C/EBP), A-1-2 (FABP4) and A-1-3 
(PPAR). 
 
Figure 3-20.  Change in C/EBP expression following adipogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed 
for expression of C/EBP by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 relative to P3.  (A) 
PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.  
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
 
 
 
Figure 3-21.  Change in FABP4 expression following adipogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed for 
expression of FABP4 by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 relative to P3.  (A) 
PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.  
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 3-22.  Change in PPAR expression following adipogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed for 
expression of PPAR by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 relative to P3.  (A) 
PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.  
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
3.3.4.3 Osteogenesis 
Changes in gene expression of osteogenic-specific markers are variable between donors and 
passages.  Cell lines PCBM1632, 110877, PCBM1641 and 127756 show a significant increase in 
RUNX2 expression with increasing passage (Figures 3-23A, 3-23B, 3-23D, and 3-23G 
respectively).  Changes in gene expression of ALPL and SPP1 are more variable due to 
passaging.  Cell lines PCBM1632, 167696, PCBM1662 and 127756 trends toward decreasing 
expression of ALPL with increasing passage (Figures 3-24A, 3-24C, 3-24E, and 3-24G 
respectively).  SPP1 expression decreases from P3 to P7 in cell lines 110877, 167696, 
PCBM1641, and PCBM1662 (p<0.0001, Figures 3-25B, 3-25C, 3-25D, and 3-25E respectively).  
A re-representation of the data as a donor comparison for all osteogenesis-related genes can be 
seen in Appendix A, Figures A-2-1 (ALPL), A-2-2 (RUNX2), and A-2-3 (SPP1). 
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Figure 3-23.  Change in RUNX2 expression following osteogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed 
for expression of RUNX2 by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 relative to P3.  (A) 
PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.  
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
 
 
 
 
 
 
Figure 3-24.  Change in ALPL expression following osteogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed for 
expression of ALPL (Alkaline Phosphatase) by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 
relative to P3.  (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) 
PCBM1655.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 3-25.  Change in SPP1 expression following osteogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed for 
expression of SPP1 (osteopontin) by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 relative to 
P3.  (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) 
PCBM1655.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
3.3.4.4 Chondrogenesis 
Following chondrogenic differentiation, expression in Sox9 decreased in most cell lines due to in 
vitro culturing from P3 to P7 (p<0.01, Figure 3-26).  Conversely, cell line 8F3560 increased in 
Sox9 expression with passaging (p<0.05, Figure 3-26F).  Aggrecan expression also decreased at 
P3 to P7 in most cell lines, which was statistically significant (p<0.0001, Figure 3-27).  Cell lines 
167696 and 127756 increased with passage, however only cell line 167696 was significant 
(p<0.0001, Figure 3-27).  Col2A1 expression was assessed, however only cell lines PCBM1641 
and 110877 at P3 showed a fold change in expression at approximately 2.5 and 3.9 respectively 
(data not shown).  A re-representation of the data as a donor comparison for all chondrogenesis-
related genes can be seen in Appendix A, Figures A-3-1 (Sox9) and A-3-2 (ACAN). 
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Figure 3-26.  Change in Sox9 expression following chondrogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 15 days in chondrogenic differentiation medium, and 
assessed for expression of SOX9 (SRY (sex determining region Y)-box 9) by qRT-PCR.  Data is expressed as mean 
± standard deviation; p<0.05 relative to P3.  (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) 
PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 
 
 
 
 
Figure 3-27.  Change in ACAN expression following chondrogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 15 days in chondrogenic differentiation medium, and 
assessed for expression of ACAN (Aggrecan) by qRT-PCR.  Data is expressed as mean ± standard deviation; p<0.05 
relative to P3.  (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) 
PCBM1655.  *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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3.4 DISCUSSION 
MSCs are of great interest because of their potential clinical application in treating many 
diseases due to both their immunosuppressive properties as well as application in tissue 
regeneration (91).  Because MSCs exist at low levels in the bone marrow (0.001 – 0.01%) (78), 
extensive expansion from multiple donors will be required to achieve numbers necessary for 
desired applications.  Therefore, establishing the role of passaging and donor differences through 
the use of quantitative bioassays will be necessary to measure these changes.  Here, it was 
demonstrated that limiting dilution was used successfully to detect changes in adipogenic 
potential following differentiation between 2 cell lines at P3, P5, and P7 (74).   The simplicity of 
the limiting dilution assay also allows for its use in almost any laboratory.  However, this assay 
is subjective due to its reliance on an individual to discern between an adipocyte and an 
undifferentiated MSC.  Further, because limiting dilution requires a dilution of MSCs as part of 
the assay setup and analysis, it may inherently ignore community effects (cell-cell and cell-
environment interactions), as Schinkothe et al. have demonstrated cytokine secretion profiles of 
MSCs include factors involved in proliferation and differentiation (92). Lastly, the time required 
for an individual to scan each well of 3, 96-well plates for each experiment is significant. 
Automated microscopy addresses these concerns with limiting dilution, as MSCs are plated at an 
identical cell density, while also introducing an efficient, automated measurement that eliminates 
any subjectivity in the analysis.  We have taken advantage of these desirable features of 
automated microscopy to quantify both adipogenic and osteogenic differentiation potential as a 
function of cell line and passage. 
Automated microscopy is inherently precise, as identical parameters are used during each 
analysis to quantify differentiated MSCs using the same automated procedure (macro).  
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Automated microscopy was applied to 8 cell lines following differentiation to quantify 
adipogenic and osteogenic potential at P3, P5 and P7 where applicable.  To determine the 
accuracy of the macro in quantifying true differentiated cells, differentiated adipocytes were 
manually counted following adipogenic induction on the identical image set acquired for 
PCBM1632.   As seen in Figure 3-5, the macro is an accurate representation of the number of 
differentiated cells, based on very similar measurements at P5 and P7 between the automated and 
manual counts, while still close at P3.  Taken together, this demonstrates both the precision and 
accuracy of automated microscopy in quantifying differentiated MSCs following adipogenic 
differentiation.  Further, when considering computation time, the macro closely predicts actual 
values in close to 1% of the time it takes to manually count an image set.  This result points to 
the utility of automated microscopy as a high-throughput tool to quantify differentiation in 
MSCs.  
Following automated analysis of all cell lines at P3, P5, and P7, we have successfully 
demonstrated that adipogenic differentiation can be quantified on a per cell basis, allowing us to 
determine the percentage of cells capable of adipogenic differentiation.  As seen in Figure 3-4, 
this percentage is highly variable between cell lines, ranging from 0.51% in cell line 8F3560 to 
13.62% in cell line PCBM1632 at P3.  The effect of donor variability becomes less significant by 
P7, where percent differentiation converges to a level of around 2% differentiation in most cell 
lines.  All cell lines except 8F3560 show a highly significant (p<0.001) drop in adipogenic 
potential when comparing P3 v. P7.  Because automated microscopy provides a quantitative 
readout of differentiation capacity, we were able to measure differences between cell lines and 
passages on a per cell basis.  As there has been little effort in the field to quantify differentiation 
in MSCs, many researchers utilize qualitative (i.e. Oil Red O staining (93-95)) or semi-
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quantitative (pixel quantitation or spectrophotometry following isopropanol extraction of Oil Red 
O-stained adipocytes (72,80) measurements to demonstrate differentiation capacity. However, 
without a quantitative bioassay that measures differentiation on a per cell basis, these differences 
cannot be truly measured to determine changes in varying populations of MSCs as a result of 
donor variability or passaging.   
A similar methodology was utilized to quantify osteogenic differentiation by automated 
microscopy.  Because of the morphological differences in the osteogenesis-differentiated 
phenotype, quantitative analyses had to be based on thresholding and subsequent surface area 
quantification, as there was no all-or-none response to osteogenic stimulation.  Therefore, ALP 
staining was utilized to represent positive osteogenic differentiation, and ALP-positive area was 
normalized to nuclei counts.  Interestingly, our data suggests osteogenic potential correlates with 
proliferative capacity in MSCs, as shown in Figure 3-9.  However, normalization to nuclei 
counts still demonstrates that osteogenic differentiation capacity decreases as a result of 
passaging.  Further, a high degree of donor variability at P3 was demonstrated based on the 
ability to form bone in vitro, as shown in Figure 3-8.  Similar to adipogenic potential, P7 
osteogenic-differentiated cells show more homogeneity between donors as demonstrated by an 
overall decreased potential.   
Although not genetically identical as in a mouse-model system, it is interesting to point 
out the differences in osteogenic potential based on gender.  The cell lines demonstrating the 
largest degree of osteogenic differentiation potential are those derived from male donors 
(PCBM1632 and 127756), while those showing the least amount of osteogenic differentiation are 
derived from females (PCBM1655, PCBM1662, and 167696).  The role of gender differences in 
the ability to form bone in MSCs (96) and other cell types (97,98) has been documented, and it is 
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of note that our in vitro quantitative bioassay to measure osteogenic capacity can detect these 
differences.   In regards to bone formation, male murine muscle-derived stem cells (MDSCs) 
show enhanced bone forming capacity based on ectopic bone formation in a cranial defect 
wound healing model (98).  Others have demonstrated this in adipose-derived stem cells (ASCs) 
derived from male rabbits via an increase ALP-positive staining following osteogenic 
differentiation (99).  Conversely, ASCs derived from female mice show increased expression of 
PPAR, a major transcriptional factor involved in adipogenesis (100).  Interestingly, female bone 
marrow-derived MSCs have demonstrated improved response to activation by hypoxia via 
increases in VEGF secretion and decreases in secretion of pro-inflammatory cytokine TNF-
when compared to male bone marrow-derived MSCs (101).  Taken together, these studies 
suggest a potential role of gender that is lineage-specific, and therefore may be considered as a 
potential factor in clinical applications (102).   
To substantiate our quantitative measurements of adipogenic and osteogenic 
differentiation potential, we investigated changes in lineage-specific differentiation markers on 
the molecular level by qRT-PCR.  In regards to adipogenesis, changes in gene expression appear 
to be in line with automated measurement results, showing a general trend toward decreasing in 
expression with increasing passage.  While cell line 8F3560 appears to be the most variable in 
regards to expression of adipogenic-specific markers, the overall change in gene expression of 
this cell line is low relative to other cell lines, and therefore the level of detection may allow 
contribution of noise.  Changes in osteogenic gene expression are more variable.  Interestingly, 
expression of RUNX2 uniformly increases in all cell lines, however it has been shown that 
expression of RUNX2 in late stages of differentiation inhibits maturation of osteoblasts, which 
correlates with the decreased ALP as quantified by automated microscopy.  With the exception 
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of cell line 8F3560, the hallmark transcription factor involved in chondrogenesis Sox9 shows a 
decrease in expression with passage, which correlates with our qualitative assessment of 
chondrogenesis by Alcian Blue staining.  While Col2A1 expression was not detected, it is likely 
due to the time point in which chondrogenic differentiation was assessed by qRT-PCR.  In 
general, while some of these patterns behave as would be predicted by biological outcomes 
based on quantitative assessments, others do not.  Changes in gene expression are temporal, and 
variability between donors may be due to the kinetics of specific gene responses.  Therefore, 
gene expression may be a poor substitute to assess differentiation capacity compared to 
quantitative bioassay assessments.  
Because the macro quantifies differentiated cells, the total nuclei count per image is also 
recorded.  When plotting this data alone in differentiated and in undifferentiated controls, the 
overall proliferative potential of each cell line at varying passages can be inferred.  As seen in 
Figure 3-6, this data demonstrates that upon adipogenic stimulation, the overall proliferative 
potential decreases in MSCs when compared to corresponding undifferentiated controls.  
Further, this data also suggests that the overall proliferation decreases with increasing passage in 
both differentiated and undifferentiated samples, and this can also vary between cell lines.  
Similar trends in decreased proliferative potential with passage was also seen in osteogenic-
induced MSCs (Figure 3-10) 
This decrease in proliferation and adipogenic/osteogenic capacity with passage, as 
demonstrated by automated microscopy, also correlates with the decrease in percent CFUs with 
passage, as seen in Figure 2-5 and discussed in Chapter 2.0.  As outlined by Prockop et al., 
MSCs capable of clonal expansion are more proliferative and have a greater capacity to 
differentiate (75).  Interestingly, cells from the 2 oldest donors (127756 and PCBM1655), which 
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were not capable of expansion beyond P5 and P3 respectively, both had the lowest CFU 
percentage at P3 (Figure 2-5), and also had the lowest proliferation potential as shown in Figure 
2-1).  In addition, both of these cell lines had the largest average cell diameters (Figure 2-4) 
which also correlated their respective FSC/SSC size data (Figure 2-3).  This suggests donor age 
may play a role in growth potential and CFU capacity, which in turn correlates with cell size.  
Others have shown the function of cell size as well, as Colter et al. demonstrated a high 
correlation with recycling stem cells (a subpopulation of small, agranular, rapidly proliferating 
cells) and CFU capacity compared to the large, granular mature MSCs that are a slow growing 
subpopulation (103).  Stenderup et al. also showed MSCs from younger donors had improved 
proliferative capacity over older donors based on higher cumulative population doublings and a 
lower percentage of senescence-associated beta-galactosidase (76).  However, despite the 
decrease in percent CFUs and increase in cell size seen in both of these cell lines at P3, both cell 
lines 127756 and PCBM1655 had the 2nd and 3rd highest percent adipogenic differentiation when 
compared to cells from other younger donors at P3.  While this finding goes against our 
hypothesis that those MSCs with the lowest CFU capacity and largest cell diameters would be 
less likely to differentiate, there may be multiple factors at play.  Many have hypothesized a shift 
from high osteogenic and low adipogenic capacity in young donor MSCs to a low osteogenic and 
high adipogenic capacity in older donor MSCs due to the downregulation of osteogenesis-
associated genes with age (104,105).  In many cases, aging leads to a decrease in bone mass, as 
seen in osteoporosis, while typically accompanied by larger number of adipocytes in the bone 
marrow (73).  This proposed inverse relationship between adipogenesis and osteogenesis has 
been reviewed extensively by Kim et al (106).  Almeida et al. have suggested that this shift may 
be in part due to oxidative stress during aging, through the involvement of FoxO transcription 
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factors that are cellular mediators of oxidative stress (107).  Taken together, this paradigm 
describing the shift from osteogenesis to adipogenesis in the bone marrow as we age, may 
partially explain our findings described here.  Overall, however, decreased differentiation 
potential with passage is consistent amongst adipogenic and osteogenic lineages.   
Others describe this osteogenic to adipogenic shift in MSCs to correlate with in vitro age, 
or passaging.  Kim et al. demonstrated that after culturing MSCs up to passage 15 in both 
adipogenic and osteogenic-inducing media, there is a decrease in Von Kossa staining, while an 
increase in adipogenesis was shown by Oil Red O staining with increasing passage.  Further, 
they correlated this shift in potential with increasing passage with an increase in senescence-
associated beta-galactosidase staining, suggesting senescent MSCs are still capable of adipogenic 
differentiation (106). Unlike other published literature which relies only on cell population 
staining to demonstrate differentiation, adipogenic and osteogenic differentiation was quantified 
on a per cell basis in MSCs using automated microscopy.  With a quantitative readout on 
differentiation, automated microscopy (in conjunction with other previously established 
quantitative bioassays) allows us to measure both the role of passaging and donor variability on 
MSC differentiation capacity, and therefore in turn correlate differentiation capacity with other 
cell properties. 
MSCs are also partially defined by their ability to undergo chondrogenesis.  Due to the 
nature of the in vitro differentiation assay by pellet culture, we have not yet quantified 
chondrogenic differentiation on a per cell basis.  Nonetheless, to obtain a full overview of the 
differentiation potential of the cell lines used in this study, we wanted to assess chondrogenic 
differentiation potential as it relates to donor and passage differences.  Based on a qualitative 
assessment, we do see slight differences in chondrogenic potential between donors, as some 
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donors appear to have more positive staining for sulfated GAGs by Alcian Blue than other 
donors (Figures 3-11 to 3-18).  Further, it appears that most donors have more positive Alcian 
Blue staining at P3 than at P7, indicating in vitro culture may decrease chondrogenic potential 
with passage.  Decreased expression in Sox9 and Aggrecan due to passaging in most donors 
(Figures 3-26 and 3-27) also supports our qualitative assessment.    
Both researchers and manufacturers of MSCs use cell surface markers to characterize 
MSCs.  As outlined in a white paper published by the ISCT, it is accepted in the field that MSCs 
should be plastic-adherent cells that are positive for CD73, CD90 and CD105, negative for 
CD14, CD34, CD45, CD79a, and HLA-DR, and capable of tri-lineage differentiation (29).  Our 
findings demonstrate that while MSCs maintain positive expression for CD73, CD90, CD105, 
and other relevant MSC markers (Figure 2-2), this maintenance of positive expression does not 
correlate with their decreased functionality/differentiation capacity as demonstrated by 
automated microscopy.  In other words, expression of these cell surface markers does not 
correlate with maintenance of adipogenic or osteogenic precursors through passaging.  Further, it 
is widely accepted that trilineage differentiation is a required characteristic of MSCs, but 
quantitative assessments of this capacity are not often reported.  To date, it has been acceptable 
in the literature to show differentiation by simple staining techniques, or by semi-quantitative 
methods that do not take into account the inherent heterogeneity of MSCs by quantifying on a 
per cell basis.  Here, an efficient method to quantify adipo- and osteogenesis was developed, 
while also assessing the effects of passaging and donor variability on differentiation capacity in 
vitro.  By quantifying differentiation capacity, we are also able to correlate these findings with 
other quantitative bioassay readouts to provide an overview of donor variability while also 
assessing the effects of culturing on MSC stemness and potency. 
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3.5 CONCLUSION 
Quantitative assessments of the biological characteristics of MSCs will allow for the detection of 
donor and passage-specific differences and may be of great utility in discovery of molecular 
markers that correlate with differentiation and proliferation capacity of MSCs.  Further, these 
quantitative measurements may also help assess various growth conditions (serum v. serum free), 
the addition of exogenous growth factors, the role of oxygen conditions, etc. to better understand 
the role of these parameters in a quantitative readout.  In this chapter, limiting dilution was 
shown to be capable of determining a precursor frequency that provides a quantitative measure 
of the adipogenic differentiation capacity in populations of MSCs.  Further, automated 
microscopy was also shown to be a technique that can quantify adipogenic and osteogenic 
differentiation on a per cell basis.  Future work will focus on quantitative assays to assess 
chondrogenic differentiation in vitro.  Lastly, it was shown that differentiation capacity varies 
between MSCs from different donors and passages, and that mean cell size increases with cell 
passage.  The next chapter will focus on cell size and assessing MSC characteristics and 
differentiation capacity in sorted small and large cells, as well as determining a mechanism of 
action as it relates to differentiation capacity and senescence in MSCs while utilizing quantitative 
bioassays discussed in Chapters 2 and 3. 
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4.0  DETERMINATION OF THE ROLE OF CELL SIZE AND WNT SIGNALING IN 
DIFFERENTIATION AND SENESCENCE OF MSCS USING QUANTITATIVE 
BIOASSAYS 
4.1 INTRODUCTION 
4.1.1 MSCs and cell size 
The role of cell size in MSC behavior has been previously described in earlier literature, where 
Mets and Verdonk showed MSCs in early passages were heterogeneous containing both small, 
rapidly-dividing spindle-shaped cells, and large, slowly-dividing cells (108).  At later passages, 
cultures became more homogeneous, predominantly containing the large, slow dividing cells that 
are closer to senescence.  This shift in heterogeneity was also associated with decreased potency 
and proliferation capacity.  Colter et al. later identified the small, agranular cells as “recycling 
stem cells” (RS cells) and the large, granular cells as mature MSCs (mMSCs).  The number of 
RS cells also highly correlated with the percent CFUs, indicating early progenitors reside in the 
RS population of MSCs, and are responsible for the rapid expansion of MSCs in vitro (13,103).   
Many others have documented changes in cell size in response to in vitro culture.  More 
recent studies have reported these changes using flow cytometry to measure FSC (size) and SSC 
(granularity).  Larson et al. have shown that the percentage of cells in the high FSC/SSC 
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quadrant increases with time in culture, while the percentage of cells in the low FSC/SSC 
quadrant decreases with time in culture.  Further, they also document that this may be a result of 
cell density, as replated cells after confluence at a lower density will revert back to the ‘RS’ cells 
described above (84). 
In our own work, as seen in Chapter 2, we have also documented an increase in cell size 
and granularity with increasing passage by flow cytometry.  We have also validated this by 
quantifying cell diameter using a cell counter, which has the capability of measuring cell 
diameter when counting cells.  While many have correlated this increase in cell size with 
decreased stemness and potency, few have separated small and large cell populations to study 
purified cell populations.  In this chapter, we have taken advantage of the cell size heterogeneity 
seen in MSCs to directly evaluate the role of cell size on potency and stemness through two 
different methods.  Enrichment of small cell progenitors in MSCs may allow for the identity of 
novel stemness markers that correlate with improved MSC function in vitro and in vivo, and an 
improved understanding of signaling pathways involved in stem cell maintenance in the small 
cell subpopulation. 
4.1.2 Wnt Signaling in MSCs 
In regards to differentiation, inhibition of Wnt signaling has been shown to be necessary for 
adipogenic differentiation (109).  Canonical Wnt signaling in MSCs inhibits expression of 
adipogenesis-related transcription factor PPAR in MSCs (110).  In line with this, it has been 
suggested that downstream targets of Wnt signaling, namely cyclin D1 and c-myc, regulate 
adipogenesis through the respective inactivation of PPAR and C/EBP (111,112).  The role of 
Wnt signaling in osteogenesis is less clear, as differential effects have been reported.  Exogenous 
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addition of Wnt3a, a Wnt agonist, has been shown to both enhance (113-115), and inhibit 
(11,71), osteogenesis.  Further, Wnt signaling may improve differentiation in osteogenic lineage-
committed MSCs, while terminal differentiation was inhibited in mature osteoblasts (116-118).  
Further, -catenin may be a functional positive and negative regulator of chondrogenesis.  
Lithium ion-induced -catenin accumulation decreased chondrogenesis as shown by decreases in 
Alcian Blue-positive staining for collagen type II in chick embryo wing chondroprogenitors 
(119).  However, siRNA knockdown of -catenin has also been shown to decrease expression of 
collagen type II and aggrecan by RT-PCR (119).   
The canonical Wnt signaling pathway can be modulated by various methods.  Secreted 
frizzled-related proteins (sFRPs) act as Wnt antagonists and inhibit Wnt signaling through 
binding of Wnt ligands (120) or frizzled protein receptors (121).  sFRP has been shown to 
positively regulate proliferation and wound repair.  Specifically, sFRP enhances the proliferative 
capacity of human MSCs (122), while Mirotsou et al. demonstrated sFRP is involved in 
myocardial repair in MSCs (123).   In this chapter, we will utilize a sFRP inhibitor to block Wnt 
signaling to better understand the role of Wnt signaling in proliferation and differentiation. 
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4.2 MATERIALS AND METHODS 
4.2.1 FACS based on cell size 
Cell line PCBM1641 P7 cells were thawed, expanded and sterilely sorted into populations of 
small and large cells based on forward scatter (FSC) properties using the FACS Aria (BD 
Biosciences).  FSC correlates with cell size, therefore separate sorting gates were applied to 
approximately the upper (large cells) and lower (small cells) thirds of an FSC histogram plot.  
For example, for one experiment with PCBM1641 P7 cells, this corresponded to a gate from 45 
to 105 FSC units (small cells) and from 170 to 258 FSC units (large cells).  Cells in the middle 
third were not analyzed.  Sorted populations were then counted and plated for limiting dilution 
analysis as described in Chapter 2.   
4.2.2 Cell size separation via filtration 
6 x 6cm nitex meshes of 10, 15 and 20m in diameter were purchased from SEFAR.  Mesh 
holders were made from Lexan (a polycarbonate), and designed to fit in standard 50ml conical 
tubes.  Holders are comprised of 2 separate components, an inner and outer ring, designed to 
allow the nitex mesh square fit tightly in between.  Mesh holders were fabricated by Mechanical 
Instrumentation Design and Fabrication Branch at the National Institutes of Health.  Figure 4-1 
shows a schematic of the filter rings and corresponding dimensions. 
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Figure 4-1.  Schematic of ring assembly 
used for cell size separation and size 
dimensions of inner and outer rings.  
Nitex meshes fit tightly in between inner 
and outer rings. Dimensions displayed in 
inches. 
 
 
 
P5 cells from cell line PCBM1632 were thawed and expanded until 80% confluent.  Cells 
were trypsinized, counted, and resuspended in expansion medium at 100,000 cells/ml.  The cell 
suspension was first applied to the 20m mesh and allowed to passively drip through the 
column, leaving cells greater than 20m on top.  Flow through < 20m in diameter was collected 
and passed through the 15m mesh.  To collect the cells >20m, the filter rings were separated, 
and the top of the mesh was rinsed with 500l of expansion medium and collected.  This 
procedure was repeated to collect cells in the following cell size ranges: >20m, 15-20m, 10-
15m, and <10m.  Cells from each size range were spun down and counted for various 
endpoints.  Large cells were considered to be cells that did not pass through the 20m filter, and 
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small cells were considered to be cells the cells that passed through the 10m filter.  These 
numbers varied slightly between replicate experiments. The workflow for cell size separation is 
illustrated below in Figure 4-2. 
 
Figure 4-2.  Schematic of cell size separation workflow.  MSCs from PCBM1632 P5 at 100,000 cells/ml were 
applied to nitex meshes held by filter rings (not shown) to separate cells by cell size.  Cell size ranges >20m, 15-
20m, 10-15m, and <10m were collected and processed for further endpoint analysis. 
 
  
4.2.3 Inhibition of Wnt signaling 
Inhibition of Wnt signaling in MSC cell lines was carried out through exogenous addition of a 
diphenylsulfone sulfonamide derivative (Enzo Life Sciences), an sFRP-1 inhibitor and Wnt 
antagonist, to cell culture media at 5M concentration.  Optimal concentration was determined 
following a titration experiment examining proliferation potential and based on previously 
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published data (124).  To assess proliferative capacity and response of adipo- and osteo-lineage 
specific genes following differentiation in the presence and absence of sFRP-1 inhibitor, cells 
were plated as described in Section 2.2.3 to assess proliferation, and as described in section 3.2.4 
to measure changes in gene expression.   
4.2.4 Senescence-associated beta-galactosidase staining 
Following cell size separation, MSCs from the large (>20m) and small (<10m) were plated in 
6-well plates at 30,000 cells/well.  After cells were allowed to adhere for 24 hours, plates were 
processed using a senescence -galactosidase staining kit (Cell Signaling) per instructions.  
Briefly, MSCs were fixed for 15 minutes with 1X fixative solution, rinsed, and incubated 
overnight with 1ml -galactosidase staining solution in a non-CO2 incubator.  Plates were 
imaged using a Nikon Ti-S inverted microscope. 
4.2.5 Quantitative functional endpoints 
Following cell-size separation by filtering, MSCs were evaluated for CFU, proliferation capacity, 
and adipogenic and osteogenic differentiation potential as described in Chapter 3 to further 
elucidate the role of cell size in MSC biological function. 
4.2.6 Statistical Analyses 
Statistical comparisons made between small and large cells were completed using a Student’s 2-
tailed t-test in Microsoft Excel.  Likewise, statistical analyses for qRT-PCR comparing the 
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addition of sFRP-1 inhibitor were also carried out in excel using the same analysis.  Data is 
represented as an average of n=3 and p<0.05 was considered significant.   
4.3 RESULTS 
4.3.1 Wnt signaling inhibitor may improve proliferation and adipogenic capacity 
Following addition of sFRP-1 inhibitor to block Wnt signaling, MSCs at P3 appear to show a 
slight improvement of proliferative capacity.  MSCs at P7 show no response in proliferative 
capacity following Wnt inhibition (Figure 4-3). 
 
Figure 4-3.  sFRP may slightly improve proliferation at early passages in MSCs.  Cell line 110877 P3 and P7 
was cultured with (+sFRP) or without (-sFRP) at 5m until confluence.  Percent confluence was recorded using a 
live cell imager.   
 
 
MSCs at P3 and P7 were differentiated toward adipo- and osteogenic lineages for 7 days with or 
without addition of sFRP-1 inhibitor, and were examined for changes in gene expression for 
lineage-specific markers by qRT-PCR.  Addition of sFRP-1 inhibitor increases expression of 
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PPAR, C/EBP and FABP4 at P3 (p<0.05), while no effect was shown at P7 (Figure 4-4).  
Further, addition of sFRP-1 inhibitor appears to have little to no effect on osteogenic 
differentiation at either P3 or P7 (Figure 4-5).   
 
 
 
Figure 4-4.  sFRP-1 inhibitor increases expression of adipogenic-specific markers at passage 3.  Cell line 
110877 P3 and P7 was cultured with (+sFRP) or without (-sFRP) at 5m for 7 days in adipogenic differentiation 
medium.  Changes in gene expression of (A) PPAR (B) C/EBP and (C) FABP4 were assessed by qRT-PCR.  Data 
is represented as mean ± standard deviation, n=3.  *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
 
Figure 4-5.  sFRP-1 inhibitor has little effect on osteogenic-specific markers.  Cell line 110877 P3 and P7 was 
cultured with (+sFRP) or without (-sFRP) at 5m for 7 days in osteogenic differentiation medium.  Changes in gene 
expression of (A) SPP1 (B) ALPL and (C) BSP were assessed by qRT-PCR.  Data is represented as mean ± standard 
deviation, n=3.  *p<0.05. 
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4.3.2 Cell size separation by FACS 
Due to the detectable changes in the FSC profile between passages, we utilized this property to 
sort small and large cells.  We then applied the adipogenic precursor limiting dilution method to 
the sorted populations to determine whether cell size affects differentiation.  PCBM1641 cells at 
P7 were sorted into high FSC (“large” cells) and low FSC (“small” cells) populations.  The 
average cell diameter post-sort was 14.6 and 19.3m respectively.  The number of cells that were 
capable of differentiating into an adipocyte in the small population was 1 in 126 cells, while in 
the large cell population it was 1 in 296 cells, which was statistically significant (p<0.05, Figure 
4-6) 
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Figure 4-6.  MSCs of different sizes have different adipogenic precursor frequencies.  Cell size thresholds were 
based on separate FSC sorting gates that were applied to the upper (large cells) and lower (small cells) thirds of an 
FSC histogram plot.  (A) The fraction of responding wells was plotted as a function of cell dose in sorted small and 
large cells from PCBM1641 following limiting dilution analysis.  (B)  A plot of non-responding wells as a function 
of cell dose.  The trend line was used to calculate precursor frequency in populations of small and large cells.  Error 
bars represent standard deviation; n=3 for both cell populations.  R2 values were 0.99 for both small and large cells. 
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4.3.3 Cell size separation by filtering 
4.3.3.1  Cell Diameter 
Cell diameters were recorded following cell size separation to confirm the average diameter 
within each cell size range, including >20m, 15-20m, 10-15m, and <10m.  Due to cell 
deformation when passing through filters and/or cell-cell adhesions, the actual final cell size 
diameter was 23.9m in the large cell population and 14.9m in the small cell population 
(Figure 4-7).  The frequency of cells within each size range were measured in 1m bins as a 
function of cell diameter.  A representative example of the cell size separation results can be seen 
Figure 4-7.   
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Figure 4-7.  Cell size distribution summary.  MSCs from PCBM1632 P5 were separated sequentially by cell size 
into >20m (A), 15-20m (B), 10-15m (C), and <10m (D) size ranges from the unfiltered (E) population.  Cell 
diameters were measured using a cellometer.  *Note: x-axis size ranges vary in panels A-E. 
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4.3.3.2 The small cell population demonstrates increased CFU capacity 
CFU analysis is a simple method to quantify stem like progenitors in various populations of 
MSCs, as discussed in previous chapters.  Enrichment for separate small and large cell 
populations demonstrates decreased CFU capacity in the large cell population (Figure 4-8).  
Average CFU in the small cell population was 14%, and decreased to 6.7% in the large cell 
population, which was significant (p<0.05).    
 
 
Figure 4-8.  Colony forming unit capacity decreases in the large cell population.  MSCs from PCBM1632 P5 
were separated based on cell size, and plated for CFU analysis.  Red = small cells (<10m) and Blue = large cells 
(>20m). Data plotted as mean ± standard deviation, n=3, *p<0.05. 
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4.3.3.3 The small cell population demonstrates increased proliferative potential 
MSCs from size-separated small and large cell populations were assessed for proliferative 
capacity using a live cell imager capable of measuring percent confluence over time.  The small 
cell population shows an improved proliferation rate compared to the large cell population 
(Figure 4-9).   
 
 
 
Figure 4-9.  Large cell population shows 
decreased proliferative potential.  MSCs from 
PCBM1632 P5 were separated based on cell size, 
and plated for proliferation analysis.  Red = 
small cells (<10m) and Blue = large cells 
(>20m). Data plotted as mean ± standard 
deviation, n=6. 
 
 
 
 
4.3.3.4 The small cell population contains more adipogenic precursors 
Following cell size separation, adipogenic differentiation capacity was assessed by automated 
microscopy to determine changes in the frequency of adipogenic precursors in the small and 
large cell population.  The small cell population contained twice as many Nile Red positive cells 
following differentiation than the large cell population (p<0.05) as seen in Figure 4-10 below.   
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Figure 4-10.  Adipogenic capacity decreases in the large cell population.  MSCs from PCBM1632 P5 were 
separated based on cell size, and plated for adipogenesis and Nile Red quantification via automated microscopy.  
Red = small cells (<10m) and Blue = large cells (>20m). Data plotted as mean ± standard deviation, n=3 for 
small cells, n=2 for large cells, *p<0.05. 
4.3.3.5 The small cell population contains more osteogenic precursors 
Osteogenic differentiation in size-separated populations was assessed following ALP staining 
and quantification via automated microscopy and surface area quantification.  Figure 4-11 below 
demonstrates a qualitative difference in ALP expression, showing the small cell population 
(Figure 4-11B) has a greater degree of positive ALP staining than the large cell population 
(Figure 4-11A).   
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Figure 4-11.  Overall osteogenic capacity decreases in the large cell population.  MSCs from PCBM1632 P5 
were separated based on cell size, and plated for osteogenesis and imaged for ALP expression.  (A)  large cells 
(>20m) and (B) small cells (<10m).   
 
Interestingly, following a quantitative assessment of osteogenic differentiation by automated 
microscopy, a cell-by-cell analysis of the osteogenic potential of the small and large cell 
populations show no statistical difference.  Although there is an overall increase in osteogenesis 
based on a qualitative assessment of ALP staining as shown in Figure 4-12, normalization to 
nuclei counts to obtain a measurement on a per cell basis suggests there are no cell-to-cell 
differences based on cell size and osteogenic potential.   
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Figure 4-12.  Measurement of osteogenic differentiation capacity on a per cell basis suggests there are no 
differences in the small and large cell size population in the ability to form bone in vitro.  MSCs from 
PCBM1632 P5 were separated based on cell size, and plated for osteogenesis and imaged for ALP expression.  
Alkaline Phosphatase staining was quantified by thresholding (A) large cells (>20m) and (B) small cells (<10m).   
 
4.3.3.6 The large cell population contains more senescent cells 
Size-separated MSCs from cell line PCBM1632 at P5 were plated and stained for -
galactosidase after cells were allowed to adhere for 24 hours.  Staining as shown in blue 
indicates senescent MSCs reside in the large cell population as seen in Figure 4-13. 
 
 
 
  99 
 
Figure 4-13.  -Galactosidase staining in sorted small and large populations.  MSCs from PCBM1632 P5 were 
separated by cell size into small (left) and large (right) subpopulations and stained with -galactosidase, an indicator 
of senescence.  Images were taken at 10X, and positive -galactosidase is seen in blue. 
 
4.4 DISCUSSION 
Due to the inherent heterogeneity of MSCs, there is a need in the field to purify and enrich MSC 
populations for early progenitors that are capable of improving a desired outcome.  Much work is 
being done to identify novel biomarkers that may correlate with in vitro and in vivo potency 
assays that could be used to enhance stemness in MSC populations (36,39,84,125).  Here, based 
on our observations that increased cell size with passaging correlates with decreased biological 
functions, we took advantage of this cell size heterogeneity to purify small and large cell 
subpopulations to further understand the role of cell size in MSC function and stemness.  
Enrichment of different cell size populations will also eventually allow us to identify markers 
and understand the role of various cells signaling pathways that are associated with the small and 
large cell phenotype.   
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 Our first attempts to isolate small and large cell populations were based on observations 
of an increase in forward (FSC) and side scatter (SSC) with passage as seen by flow cytometry.  
By gating on low FSC/SSC MSCs to enrich for small cells, and conversely high FSC/SSC to 
enrich for large cells, we were able to successfully isolate enrich small and large subpopulations 
by FACS (74).  While this was effective to show a significant increase in adipogenic potential by 
limiting dilution, there was likely small cell contaminants in the large cell population that may 
have contributed to the measured potential of the large cell population.  Further, cell sorting 
requires cells to be out of culture for hours during a sort, which is not ideal.  We therefore moved 
toward creating a simple filtering device to separate cells based on cell size.  While standard cell 
filters exist, their pore sizes are too large to filter within particular cell size ranges.  We therefore 
created a simple filter apparatus designed to fit in standard 50ml conical tubes, and capable of 
tightly fitting a mesh size of our choosing to separate specific cell diameters with precision.  
While straightforward, few investigators have enriched for MSCs based on a cell size metric to 
study specific cell size populations.   
As seen in Figure 4-7, we demonstrated that our filtering ring apparatus successfully 
separates cells based on cell size.  While our cell size measurements may or many not represent 
the filter size range indicated, cells are fluid and cells larger than the designated filter size may 
partially deform and passively pass through the filter.  Nonetheless, we show a 9m difference in 
cell size between the small and large cell populations, which was significant enough to show 
functional differences based on our quantitative measurements.   
Our data confirms that early progenitors primarily reside in the small cell population.  As 
seen Figure 4-9, the small cell population has greater proliferative potential than the large cell 
population, which correlates with increased CFU capacity (p<0.05, Figure 4-8) and decreased 
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senescence as shown by -galactosidase staining in Figure 4-13.  Further, small cells show 
enhanced ability to undergo adipogenic differentiation, which was statistically significant 
between the two cell size populations, both by limiting dilution and by Nile Red quantification 
(p<0.05, Figures 4-6 and 4-10).  Based on a qualitative, population-based assessment of 
osteogenic differentiation by ALP staining, it appears as though the small cell population has 
improved capacity overall to undergo osteogenesis (Figure 4-11).  However, based on our 
quantitative measurements of osteogenesis on a per cell basis, it appears as though there are no 
differences in osteogenic potential based on cell size (Figure 4-12).  Based on the correlation of 
the binary area fraction to nuclei counts as shown in Figure 3-9 in Chapter 3, this suggests 
osteogenic potential may be closely tied to proliferative capacity.  Because the small cell 
population can readily proliferate and there are therefore inherently more cells at the end of a 14-
day differentiation experiment, this may explain why there is an overall increase in ALP staining 
in the small population, but no differences on a per-cell basis.  Due to MSC heterogeneity, it is 
important to quantify differentiation on a cell-by-cell basis.  However, it appears as though 
unlike adipogenic differentiation, following osteogenic differentiation there is a more 
homogeneous response that is not cell-size dependent.  Therefore, differences may more so 
depend on cell source from different donors, as well as the overall proliferative potential of a 
particular cell line.   
When considering MSC heterogeneity, it is interesting to consider the idea that these 
distinct cell size populations may need to co-exist.  While enhanced proliferative potential was 
demonstrated in the small cell population as shown in Figure 4-9, one particular observation of 
interest is that the small cells become large cells rapidly in culture following cell size separation, 
suggesting a role of the large cell population in maintaining the small, stem-like population.  
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While it is shown here that the large cells are inactive by their decreased proliferative potential 
and CFU capacity, they perhaps have a contact-dependent and/or secretory role in maintaining 
stemness in the small cell population.  Future experiments elucidating the secretome of cell size-
separated MSCs may point to a paracrine role of the large cell population in maintaining the 
stem-like phenotype in the small cell population.   
To better understand the mechanism behind decreased function with passage beyond 
changes in cell size, the role of Wnt signaling and its potential role in proliferation and 
differentiation in MSCs was evaluated.  An sFRP-1 inhibitor was utilized to block Wnt signaling 
in vitro and measured changes in proliferative capacity and gene expression of adipo- and 
osteogenic-specific markers by qRT-PCR in cell line 110877 at P3 and P7.  It has been 
previously documented in the literature that blocking Wnt signaling may improve adipogenesis 
and proliferation in MSCs.  Here, the addition of a Wnt signaling inhibitor demonstrated slight 
improvements in proliferative potential at P3, but has no effect at P7 (Figure 4-3).  Our gene 
expression data confirms previous findings based on the role of Wnt signaling as it relates to 
adipogenesis.  Following adipogenic differentiation for 7 days with or without the presence of 
sFRP-1 inhibitor, changes in gene expression of PPAR, C/EBP and FABP4 were measured, 
and show a significant increase at P3, but no differences were detected at P7 (Figure 4-4).  
Interestingly, blocking Wnt signaling during osteogenic differentiation appeared to have no 
significant effect on regulation of osteogenic-specific markers by qRT-PCR (Figure 4-5).  The 
literature does not suggest a clear role of Wnt signaling in osteogenic differentiation, and there 
are likely more relevant signaling pathways that play a role in osteogenic differentiation capacity 
(126,127).  Future work will apply quantitative assays described in Chapters 2 and 3 to assess the 
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role of additional signaling pathways in size-separated MSCs to better understand the small cell 
phenotype. 
4.5 CONCLUSION 
In this chapter, we demonstrated that the small cell population contains early progenitors capable 
of enhanced proliferation and differentiation capacity.  Small cell enrichment in MSCs may 
therefore be a useful tool to improve MSC function in vitro and in vivo for cellular therapies.  
However, more work needs to be done to understand the molecular signature of the small cell 
population as it relates to its enhanced stemness demonstrated here.  While our data suggests 
Wnt signaling may play a role in regulating adipogenic differentiation and proliferative capacity 
in MSCs, many other signaling pathways have been demonstrated in the literature to regulate 
stemness and differentiation in MSCs.   
  104 
5.0  QUANTIFICATION OF IMMUNOSUPPRESSIVE ACTIVITY IN MSCS 
5.1 INTRODUCTION 
While MSCs are known to possess a wide variety of cell surface markers and differentiate down 
several lineages, they possess a unique ability to home to a site of injury and suppress the local 
immune and inflammatory responses in vivo (128-132).  This unique potential has been utilized 
by several investigators, as MSCs are currently being used in investigational clinical trials to 
treat Graft vs Host Disease (GvHD), a common complication associated with bone marrow 
transplants (128,132-134).  MSCs may be particularly non-immunogenic due to the lack of MHC 
Class II (135,136), and their ability to release factors that suppress the host immune system 
(137).  This makes MSCs particularly attractive for their use in an allogeneic environment.  
MSCs may also suppress several T cell, B cell and Natural Killer (NK) functions (138). 
Aggarwal and Pittenger have previously investigated the role of human MSCs in 
modulating immunosuppression when co-cultured with purified sub-populations of immune 
cells.  Naïve human T cells were activated to undergo TH1 effector cell differentiation with or 
without the presence of human MSCs.  The presence of MSCs during T cell differentiation 
significantly decreased the expression of IFN-, a pro-inflammatory cytokine.  Similarly, this 
was repeated during TH2 effector cell differentiation, where co-culture with MSCs plus T cells 
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led to a significant increase in IL-4 production, therefore promoting a shift toward the anti-
inflammatory TH2 cells (138).   
A study by Le Blanc et al. investigated the alloreactivity of MSCs in vitro using a mixed 
lymphocyte culture with either allogeneic or autologous MSCs. Proliferative activity was 
suppressed in all cultures after the addition of higher concentrations of MSCs, regardless of the 
source (autologous or allogeneic), indicating the T cell responses are inhibited by MSCs 
regardless of the major histocompatibility complex.  Further, there appeared to be a dose-
dependent response in T cell reactivity as smaller doses of MSCs led to less suppression in 
mixed lymphocyte cultures.   
It has been previously established that MSCs cultured with exogenous IFN- improve 
their immunosuppressive capacity in vitro (139).  IFN- stimulation leads to upregulation of 
indoleamine 2,3-dioxygenase (IDO), which inhibits T cell proliferation.  It has been suggested 
that the response to IFN- is variable among donors, and that MSCs sourced from low IDO 
inducers may be less potent immunosuppressors.  There is currently no marker that predicts this 
responsiveness to IFN- stimulation, and there is therefore a need to better-predict IFN- 
responsiveness in MSCs derived from different human donors (140). 
MSCs expanded in vitro have been shown to undergo teleomere shortening and 
subsequently cellular senescence (141), which may ultimately affect their immunosuppressive 
capacity.  Extensive in vitro expansion of MSCs may modify their regenerative capacity and 
immunosuppressive function, and may limit their potency and survival in vivo (142).  Data from 
late passage MSCs suggests they are less effective in survival of GvHD patients than MSCs used 
at earlier passages (143). 
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Many investigators have evaluated the immunosuppressive activity by MSCs through the 
use of mixed lymphocyte (MLR) assays with lymphocytes from the same species.  However, the 
use of an in vitro xenogeneic system using clonal T cells specific for known peptide antigens will 
reduce the sources of variability that are unavoidable in traditional polyclonal MLR assays.  
Sources of variability arise due to heterogeneity of non-clonal allogeneic T cells and the use of 
pooled donors.  There is currently a need for quantitative bioassays to measure differences in 
immunosuppressive activity by MSCs from different donors, or to measure the effect of in vitro 
expansion of MSCs on their ability to immunosuppress.  In this chapter, we will evaluate the role 
of donor variability and passaging on immunosuppressive capacity in MSCs. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Cell culture 
Human MSCs were expanded as described in Section 2.2.1.  Cells from all donors were thawed 
from P3 and P7 vials (where applicable) into T175 flasks, cultured until 80% confluence in 
expansion medium, and trypsinized for use in immunosuppression assays.   
5.2.2 Mice 
Non-obese diabetic 8.3 TCR transgenic mice (NOD 8.3) and NOD/ShiLtj mice were purchased 
from Jackson Laboratories (Bar Harbor, Maine).  Mouse colonies were maintained in a 
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pathogen-free environment as per CBER’s Institutional Animal Care and Use Committee 
(IACUC).  CD8+ T cells from NOD 8.3 mice specifically recognize the Kd-restricted IGRP206-214 
epitope derived from the islet antigen IGRP (islet-specific glucose-6-phosphatase catalytic 
subunit-related protein) (144).  NOD/ShiLtj mice were used as a syngeneic source of antigen 
presenting cells (APCs).   
5.2.3 Immunosuppression assay 
Spleens and lymph nodes were isolated from NOD8.3 and NOD/ShiLtj mice, and tissues were 
disassociated with a syringe plunger over a 40m filter (BD Biosciences).  Cells from spleens 
were incubated in ACK red lysis buffer (Invitrogen).  Total spleenocytes from NOD/ShiLtj mice 
were irradiated at 4000 rads, counted using a Cellometer (Nexcelom), and plated at 4 x 106 cells 
per well in 24-well plates (Corning) in RPMI (Invitrogen) containing 10% FBS and 1% 
Penicillin/Streptomycin (Invitrogen).  IGRP peptide was added at 1g/ml per well.  Peptides 
were synthesized by the FDA Facility for Biotechnology Resources core facility.  Cells from 
NOD8.3 mice were purified over MACS columns for CD8a+ cells via negative selection 
(Miltenyi Biotec), counted, and plated at 2 x 106 cells/well.  Last, MSCs from all donors at P3 
and P7 were trypsinized and added to the wells at varying T cell:MSC ratios of 1:20 and 1:5.  
Co-cultures were kept at 37°C for 3-days.  Samples from each condition were removed for RNA 
isolation and ddPCR analyses at 48 hours.  An overview of the immunosuppression assay setup 
can be seen below in Figure 5-1.   
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Figure 5-1.  Schematic of immunosuppression assay.  Human MSCs were co-cultured with mouse T cells to 
evaluate immunosuppressive response by ddPCR, flow cytometry and cytokine array analyses.  After either 48 or 72 
hours, murine T cells were processed for endpoints listed to the right. 
5.2.4 Flow cytometry 
After 3-days in culture, murine T cells were removed from wells and labeled with antibodies 
including anti-CD8a, V8.1/8.2, anti-CD25, anti-CD69 and anti-CD62L with various 
fluorochrome conjugates (BD Biosciences).  Cells were analyzed using the FACSCanto flow 
cytometer (BD Biosciences).  For surface marker analysis in Flow Jo (Tree Star), gating analysis 
included cells that were double positive for CD8a and V8.1/8.2.   
5.2.5 Digital Droplet PCR (ddPCR) 
At 48 hours, murine T cells from all conditions were removed from cell culture, pelleted, and 
snap frozen in liquid nitrogen for later use.  For RNA preparation, pellets were thawed at 37°C, 
lysed with RLT buffer, and passed through a QIAshredder column.  Samples were then 
processed for RNA cleanup per the manufacturer’s instructions.  Total RNA was quantified 
using a NanoDrop (Thermo Scientific) and purity was determined using a Bioanalyzer (Agilent).   
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cDNA was synthesized utilizing the Quantiscript Reverse Transcription Kit according to 
the manufacturers instructions (Qiagen) at 42°C for 15 minutes, followed by inactivation at 95°C 
for 3 minutes.  Reaction mixtures were made with ddPCR 2X PCR Master Mix (BioRad) per the 
manufacturer’s instructions, and 15ng of cDNA-equivalents was added to each reaction.  Target 
gene sequences included Tbet and GATA3, transcription factors involved in T cell 
differentiation (Table 5-1).  A step unique to the ddPCR system is the generation of droplets 
following the preparation of reaction mixtures.  20l of sample was loaded into center cartridge 
wells, each cartridge containing enough for 8 samples at one time.  70l of droplet generator oil 
was added to corresponding wells.  Cartridges were secured with a gasket, and placed in the 
droplet generator.  Once droplet generation was complete, 40l of droplet/reaction mixture was 
added to 96-well PCR plates (Eppendorf).  This process was repeated for all samples, and plates 
were foil-sealed in a thermal plate sealer (Eppendorf).  Targets were amplified using a 
Touchgene Gradient thermal cycler under the following conditions: 95°C for 10 minutes; 40 
cycles of 94°C for 30 seconds and 60°C for 1 minute per cycle; 95°C for 10 minutes.   
Following amplification, plates were placed in a BioRad QX100 digital droplet reader for 
analysis using Quantasoft software (Biorad).  Data was analyzed to determine total copy number 
based on absolute quantification.  An example of the ddPCR workflow is seen below in Figure 5-
2. 
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Figure 5-2.  Schematic of ddPCR workflow.  Reaction mixture is created as during a normal PCR reaction setup.  
Prior to amplification, reaction mixture is mixed with oil and placed in a droplet generator to create thousands of 
droplets containing reaction mixture.  Droplet solution is then amplified as during normal PCR.  Droplets are then 
read in a droplet reader to report an exact copy number based on absolute quantification.    
 
 
Table 5-1. List of ABI primer/probe sets used in ddPCR. 
 
 
 
 
 
 
 
 
Gene Symbol Gene Name Assay ID 
GATA3 GATA binding protein 3 Mm00484683_m1 
Tbx21 Tbet, T-box21 Mm00450960_m1 
Actb actin, beta Mm00607939_s1 
B2m beta-2 microglobulin Mm00437762_m1 
Gusb glucuronidase, beta Mm01197698_m1 
Hsp90ab1 heat shock protein 90 alpha Mm00833431_g1 
GAPDH 
glyceraldehyde-3-
phosphate 
dehydrogenase 
Mm99999915_g1 
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5.2.6 Cytokine array 
Following the completion of each 3-day experiment, 500l of cell culture supernatant was 
collected from each experimental condition and stored at -80°C for future use.  Mouse TH1/TH2 
9-plex cytokine array multiplex assays were purchased from Meso Scale Discovery (MSD, 
Rockville, MD).  Supernatants, reagents and the array plate were brought to room temperature, 
and the plate was blocked with 25l of Diluent 4 per well.  The plate was sealed and incubated 
at room temperature for 30 minutes with vigorous shaking at 300-1000 RPM.  Samples and 
calibrators were then added to separate wells in duplicate at 25l/well, then sealed and incubated 
at room temperature for 2 hours and 300-1000 RPM shaking.  The plate was washed with 25l 
0.05% Tween/PBS three times.  25l of 1X Detection Antibody Solution was added per well, 
and plates were sealed and shaken for 2 hours as described above.  The plate was then washed 
with 150l 0.05% Tween/PBS three times, and 25l 2X Read Buffer T was added immediately 
prior to reading the plate on the SECTOR imager.   
5.3 RESULTS 
5.3.1 Human MSCs vary in their ability to modulate expression of Tbet and GATA3 in 
murine T cells 
To understand the immunosuppressive effect of MSCs on mouse T cells on the molecular level, 
transcription factors involved in T cell activation were assessed.  Following 48 hours of co-
culture with MSCs, murine T cells were analyzed by PCR for expression of activation markers T 
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bet and GATA3.  First, to determine an appropriate house-keeping gene for analysis, we used 
qRT-PCR to assess mouse T cells under in all experimental conditions (unactivated, activated, 
and co-cultured with MSCs) for expression of various house-keeping genes, including B2m, 
GUSB, HSP90ab1, 18S, and beta-actin.  Raw Ct values were plotted to assess variability 
between conditions, as seen in Figure 5-3.  Most house-keeping genes show a high degree of 
variability between conditions, and therefore are not suitable as an appropriate house-keeping 
gene for analysis.   While 18S appears to show similar values, there is a 3 Ct value difference 
between the lowest and highest expressers, and therefore again not ideal for analysis (Figure 5-
3).   
 
Figure 5-3.  House-keeping genes vary in suitability for PCR in immunosuppression assay.  Several house-
keeping genes were analyzed by qRT-PCR in unactivated, activated, and co-culture samples.  Raw Ct values are 
represented in triplicate and plotted as a function of house-keeping gene.  
 
 Due to these results outlined above in Figure 5-3, we utilized novel PCR technology to 
measure changes in gene expression via absolute quantification to report an exact copy number 
of the target of interest by ddPCR.  Tbet and GATA3 expression in murine T cells was assessed 
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by ddPCR following 48 hours in unactivated, activated, and co-culture samples.  Inhibition of T 
cell activation is variable between donors and passages, and is dose-dependent.  Cell line 
PCBM1632 demonstrates the largest inhibition of Tbet expression, showing a 3.3-fold decrease 
when co-cultured with P3 MSCs at 1:5, and a 2.3-fold decrease in copy number in P7 MSCs at 
the same dilution, suggesting P3 MSCs may be better immunosuppressors (Figure 5-4A).  
Similar trends in GATA3 expression with T cells cultured with PCBM1632 are shown in Figure 
5-5A.  Other cell lines do not show the same degree of inactivation; data from cell line 110877 
suggests poor immunosuppression, as co-culture with murine T cells shows increased activation 
and expression of Tbet upon co-culture with MSCs in both dilutions and at both passages (Figure 
5-4B).   
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Figure 5-4.  Tbet expression in mouse T cells vary and is cell line- and passage-dependent.  Changes in Tbet 
expression in murine T cells following co-culture with human MSCs were measured using the ddPCR method. Data 
is expressed as mean ± standard deviation (n=1-3), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  Ratios indicate 
the number of MSCs:murine T cells. (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 
8F3560 (G) 127756 (H) PCBM1655.   
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Figure 5-5.  GATA3  expression in mouse T cells vary and is cell line- and passage-dependent.  Changes in 
GATA3 expression in murine T cells following co-culture with human MSCs were measured using the ddPCR 
method. Data is expressed as mean ± standard deviation (n=1-3), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) 
PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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5.3.2 MSCs inhibit murine T cell proliferation 
Following 72 hours in co-culture, unactivated and activated T cells, and T cells + MSCs were 
examined for any changes in morphology.  Activated samples (Figure 5-6B) show distinct 
formation of clusters that are unique to the activated phenotype. The clustering also correlates 
with a high degree of proliferation. Upon addition of MSCs (Figures 5-6C and 5-6D), there is 
little detection of cluster formation, indicating MSCs are inhibiting this response. 
 
Figure 5-6.  MSCs modulate T cell morphology and inhibit proliferation.  MSCs were co-cultured with murine 
T cells and imaged using brightfield microscopy after 72 hours.  (A) unstimulated T cells (B) Activated T cells – T 
cells + peptide (C) T cells + peptide + MSCs 1:10 (D) T cells + peptide + MSCs 1 :5.  Image from panel B was 
taken at 4X ; images from panels A, C, and D taken at 10X. 
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5.3.3 Human MSCs downregulate expression of activation markers CD25, CD62L and 
CD69 upon co-culture with murine T cells 
Following 72 hours in culture, T cells were assessed for expression of activation markers CD25, 
CD62L and CD69 by flow cytometry.  The mean fluorescence intensity (MFI) values were 
plotted for ease of comparison between experimental groups.  All experimental groups were 
normalized to unactivated samples by subtracting the unactivated MFI value, and therefore 
appears as zero.  MSCs from most cell lines downregulate expression of CD25, CD62L and 
CD69 at P3 and P7 in a dose-dependent manner (Figures 5-7, 5-8 and 5-9).  This decreased 
expression may be passage-dependent, as most donors show a slightly improved inhibition in P7 
samples compared to P3.  Further, this downregulation of activation markers may be donor-
dependent.  Cell line 110877 shows consistently higher MFIs upon co-culture at both 1:20 and 
1:5 dilutions, indicating decreased immunosuppressive activity in all activation markers (Figures 
5-7B, 5-8B, and 5-9B).  At P7 1:20, cell line 110877 demonstrates a 4.6, 1.2 and 2.3-fold 
decrease in expression of CD25, CD62L and CD69 respectively.  Conversely, cell line 
PCBM1632 induces the largest decrease in MFI across all activation markers, showing an 
approximately 10, 37, and 5-fold decrease at P7 1:5 in CD25, CD62L, and CD69 respectively 
(Figures 5-7A, 5-8A, and 5-9A). 
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Figure 5-7.  Co-culture of human MSCs with mouse T cells downregulates expression of CD25, and varies 
between passages.  Changes in surface marker expression of CD25 in murine T cells following co-culture with 
human MSCs were measured by flow cytometry. Data is expressed as mean fluorescence intensity (MFI), n=1.  
Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) 
PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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Figure 5-8.  Co-culture of human MSCs with mouse T cells downregulates expression of CD62L, and varies 
between passages.  Changes in surface marker expression of CD62L in murine T cells following co-culture with 
human MSCs were measured by flow cytometry. Data is expressed as mean fluorescence intensity (MFI), n=1.  
Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) 
PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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Figure 5-9.  Co-culture of human MSCs with mouse T cells downregulates expression of CD69, and varies 
between passages.  Changes in surface marker expression of CD69 in murine T cells following co-culture with 
human MSCs were measured by flow cytometry. Data is expressed as mean fluorescence intensity (MFI), n=1.  
Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 110877 (C) 167696 (D) PCBM1641 (E) 
PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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5.3.4 MSCs inhibit secretion of pro-inflammatory cytokines TNF- and IFN-
It has been previously demonstrated that MSCs are capable of inhibiting cytokine secretion by T 
cells both in vitro and in vivo (145).  To assess donor and passage differences, we evaluated 
supernatants following 72 hours of co-culture with murine T cells by a Th1/Th2 multiplex 
ELISA assay.  As anticipated, secreted levels in activated samples were very high compared to 
unstimulated samples.  Following co-culture with MSCs, murine T cells showed marked 
decreases in secretion of both TNF- and IFN- in culture supernatants in a dose-dependent 
manner (Figures 5-10 and 5-11).   
  Inhibition of cytokine secretion by MSCs is variable between donors and passages.  
Inhibition of TNF- secretion by MSCs shows there is a dose-dependent response in most cell 
lines and passages.  With regard to IFN-, the extent of inhibition and lack of differences at 
different dilutions suggests further dilutions will be required to see a dose-dependent response. 
To graphically represent differences between donors, experimental groups with MSCs at both 
dilutions were normalized to activated sample values and plotted as percent activated, or an 
activation index (Figures 5-12 and 5-13).  Data for most cell lines suggest that P7 may improve 
inhibition of cytokine secretion by murine T cells.  Conversely, cell line PCBM1641 and 
PCBM1662 for IFN- (Figures 5-11D and 5-11E) and TNF- (Figures 5-10D and 5-10E) 1:5 
suggests P3 is more immunosuppressive by cytokine secretion.  Overall, MSCs from all donors 
inhibit secretion of pro-inflammatory cytokines IFN- and TNF- by murine T cells.   
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Figure 5-10.  Co-culture of human MSCs with mouse T cells inhibits secretion of pro-inflammatory cytokine 
TNF-.  Changes in cytokine secretion of TNF- in murine T cells following co-culture with human MSCs were 
measured by an ELISA. Data is expressed as mean concentration (pg/ml) ± standard deviation (n=2); *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 
110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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Figure 5-11.  Co-culture of human MSCs with mouse T cells inhibits secretion of pro-inflammatory cytokine 
IFN-.  Changes in cytokine secretion of IFN- in murine T cells following co-culture with human MSCs were 
measured by an ELISA. Data is expressed as mean concentration (pg/ml), ± standard deviation (n=2); *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  Ratios indicate the number of MSCs:murine T cells. (A) PCBM1632 (B) 
110877 (C) 167696 (D) PCBM1641 (E) PCBM1662 (F) 8F3560 (G) 127756 (H) PCBM1655.   
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Figure 5-12.  Inhibition of TNF- secretion may be donor- and/or passage-dependent. Secretion concentrations 
were normalized to activated sample values to obtain a donor comparison, and plotted as mean percent activation ± 
standard deviation, n=2. (A) TNF- 1:20 (B) TNF- 1:5.  
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Figure 5-13.  Inhibition of IFN- secretion may be donor- and/or passage-dependent. Secretion concentrations 
were normalized to the activated sample values to obtain a donor comparison, and plotted as mean percent activation 
± standard deviation, n=2. (A) IFN- 1:20 (B) IFN- 1:5.  
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5.4 DISCUSSION 
Based on their ability to immunosuppress, MSCs have been utilized in several clinical trials to 
treat many diseases including Crohn’s Disease, GvHD, multiple sclerosis and others 
(132,138,145,146).  Due to the potential for MSCs from several donors to treat many patients, 
there is a need to understand the role of donor differences through quantitative in vitro bioassays 
capable of predicting in vivo outcomes.   However, there are currently no in vitro bioassays that 
are suitable to detect differences in immunosuppressive activity in MSCs from different donors 
or passages.  Current assessment of immunosuppressive activity in MSCs is typically examined 
using a mixed lymphocyte reaction (MLR) assay using allogeneic, polyclonal peripheral blood T 
cells, which inherently ignores donor/recipient MHC class mismatch, making it difficult to assess 
and quantify a donor’s ability to immunosuppress.   
It has been previously established that MSCs can be used allogeneically, and further, may 
exert an effect in a xenogeneic setting, where human MSCs have been shown to home to injured 
sites and exert a function in mouse and rat in vivo models (147-151).  Therefore, the ability of 
human MSCs to exert their immunosuppressive effect on murine T cells in an in vitro model 
system was examined.  Once this was established and shown to be successful (Nazarov and Lo 
Surdo et al., submitted), we expanded this methodology to assess immunosuppressive activity in 
various donors and passages.  The advantages of this in vitro assay system include elimination of 
genetic and age variations between human T cell donors, while utilizing mouse T cells with 
monoclonal TCRs with known antigen specificity.  We have demonstrated that MSCs can exert 
an immunosuppressive effect not only across MHC mismatches, but also across species, making 
this model system ideal for measuring MSC function as it relates to immunosuppression.  
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Here, this methodology was extended to additional donors and passages to better 
understand the role of donor variability and in vitro expansion on immunosuppressive capacity.  
Based on endpoints studied here, including changes in gene expression, flow cytometry and 
cytokine secretion, we have shown that most donors can modulate expression of activation 
markers.  However, the data suggests some donors are more immunosuppressive than others.  
Based on Tbet and GATA3 expression, cell line PCBM1632 appears to downregulate expression 
of these markers based on their relative activated expression.  Flow-based endpoints showing 
decreased expression of CD25, CD62L and CD69, as well as inhibition of pro-inflammatory 
cytokine secretion, confirm these findings, and suggest that cell line PCBM1632 may be a more 
potent immunomodulator.  Conversely, cell line 110877 appears to be less immunosuppressive in 
our model system.  Data shows less downregulation of activation markers relative to stimulated 
(activated) samples.  Taken together, this data suggests there may be donor variability in 
immunosuppressive capacity that can be detected in our in vitro assay system.   
The reason for potential donor differences detected here may be due to the disease status 
of the donor, or other biological factors. We currently do not know the disease status of the 
donors from which our cell lines were derived.  Cell lines obtained from donors having an 
autoimmune disease may be less potent than those derived from healthy donors, and may 
ultimately alter their immunosuppressive function.  Further, even cell lines derived from healthy 
donors may show donor-to-donor variability.  Francois et al described the relationship between 
indoleamine 2,3-Dioxygenase (IDO) upregulation through IFN- and TNF- stimulation and 
immunosuppressive capacity by human MSCs in MSC/activated PBMC co-culture experiments. 
Interestingly, upon cytokine stimulation with the above mentioned factors, MSCs differed in 
their level of expression of IDO, and expression of IDO directly correlated with 
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immunosuppressive capacity based on T cell suppression.   This study suggests that MSCs from 
a variety of healthy donors may also demonstrate a wide range of immunosuppressive capacity.  
Another potential source of functional variability may be due to in vitro expansion of 
MSCs to obtain sufficient numbers for treatment.  A recent review by Jacques Galipeau suggests 
a role in expansion and subsequent cryopreservation of MSCs through a comparison of clinical 
treatment of GvHD in the United States and Europe.  Interestingly, clinical trials treating GvHD 
in Europe minimize cell expansion by deriving many different cell lines from many donors with 
success.  In the US, MSCs from very few donors are expanded extensively to obtain similar 
numbers for treatment, which has shown negative results (140).  Further, clinical data from the 
Karolinska Institute has shown less expansion may improve survival rates in patients with 
GvHD.  Those treated with low passage MSCs (passage 1-2) had a one year survival rate of 
75%, compared to those who were treated with later passage MSCs (passage 3-4) who had only a 
14% survival rate (143).  Taken together, this suggests a negative role of extensive in vitro 
expansion in the immunoregulatory function in MSCs.   
Interestingly, our data suggests a slight improvement in immunosuppressive function 
from P3 to P7, pointing to a potential secretory role of MSCs in immunoregulation in our in vitro 
system.  However, future experiments to determine whether or not this effect in our system is 
valid can include IFN-/TNF- stimulation and subsequent regulation of IDO expression as 
described by Francois et al (152).  Further, it is necessary to correlate our in vitro data with in 
vivo outcomes, which are currently being explored in a murine autoimmune type I diabetes 
model. 
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5.5 CONCLUSION 
We have demonstrated human MSCs can be immunosuppressive in a xenogeneic in vitro model 
system, making it an ideal system to study human MSCs from several donors and passages.  
However, more work needs to be done to correlate these in vitro data with in vivo outcomes, to 
better understand the role of donor variation and passaging on immunosuppressive capacity in 
MSCs.  A better understanding of the mechanism of action of immunosuppressive activity may 
help identify novel therapeutic targets for cellular therapies to enhance immunomodulatory 
function in MSCs. 
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6.0  OVERALL CONCLUSIONS 
MSCs hold great therapeutic potential, however MSC heterogeneity between donors and within 
populations of MSCs necessitate a better understanding underlying the mechanisms of and 
influence on MSC function that ultimately could be related to clinical outcome.  Further, in vitro 
expansion is inherently required as the fraction of MSCs in the bone marrow is low.  As 
discussed in Chapter 1, the overarching goal of this work was to improve characterization of 
bone marrow-derived MSCs through the use of quantitative bioassays.  As MSCs have several 
facets of clinical relevancy, these quantitative functional assays must address their ability to 
proliferate, differentiate, and provide an immunomodulatory function.  It is the hope that these 
quantitative bioassays can correlate with in vivo outcomes.  In Chapters 2, 3 and 5, we addressed 
these properties of MSCs through the use of both existing and novel bioassays to measure MSC 
functional activity.  Due to the inherent heterogeneity of MSCs, in Chapter 4 we took advantage 
of these heterogeneities and morphological differences by enriching based on cell size using two 
different techniques.   
In this work, we utilized MSCs from eight different donors to better understand the role 
of donor variability in MSC function.  Based on our data, it is clear that in vitro potential is 
donor and endpoint specific.  In Chapter 2, we assessed the biologic activity of the eight cell 
lines through existing bioassays, including CFUs, proliferation, and marker phenotype 
expression by flow cytometry.  Further, we also documented by several methods that MSCs 
  131 
increase in cell size with passage, and that this may correlate with decreased potential.  
Interestingly, decreased proliferative and CFU capacity do correlate with this increase in cell 
size.  Of note, however, is that expression of commonly used MSC markers to identify MSCs do 
not change with passage or between donors.  While the ISCT put forth a white paper defining 
MSCs through expression of CD73, CD90 and CD105, we clearly demonstrate that this does not 
correlate with decreased potential or function as shown by other endpoints.  Therefore, although 
these markers may be necessary to identify an MSC, they do not correlate with changes in 
biological functions between donors or with in vitro culture.  
There has been little effort to quantify differentiation capacity in MSCs.  Quantitative 
measurements of differentiation are necessary to assess biological activity between populations 
of MSCs derived from different donors.  Further, due to MSC heterogeneity, it is important that 
these quantitative bioassays measure activity on a per cell basis.  In Chapter 3, we measured 
changes in adipogenic and osteogenic potential using novel quantitative assays that can measure 
differentiation on a per cell basis.  While we were able to show differences between 2 donors 
using a limiting dilution assay, we moved toward more objective, high-throughput measurements 
using automated microscopy.  Through this methodology, we were able to identify donor and 
passage differences in adipo- and osteogenic potential in a quantitative readout.  These methods 
will have utility in donor screening to assess differentiation capacity quantitatively. Further, 
these quantitative measurements could be used to make precise measurements that allow for 
comparisons of differentiation potential in a variety of different in vitro growth conditions and 
determine the influence of many other factors that could affect MSC biological function. Once 
established, these quantitative methods to measure differentiation provide a toolbox so that other 
researchers can measure differentiation capacity in MSCs.  While we assessed chondrogenic 
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differentiation capacity qualitatively, future work will focus on using similar automated methods 
to improve quantification of chondrogenesis in vitro.   
As shown in Chapter 2, and elsewhere in the literature, MSCs are highly heterogeneous 
(64,153).  Much of this heterogeneity may be tied to morphological differences within a 
population of MSCs.  We documented these changes in cell size through passaging, 
demonstrating an increase in size and granularity by flow cytometry, and an increase in cell 
diameter though cellometer measurements.  We took advantage of these cell size heterogeneities 
and used cell size as a metric that can be used to enrich MSCs, and to study these cell size 
populations separately.  We initially used flow cytometry as a means to separate cells based on 
their FSC/SSC properties.  Due to the required time out of culture to perform a cell sorting 
experiment, we wanted to design a simpler, faster way to separate cells by size.  In Chapter 4, we 
designed a simple filtering apparatus that can accommodate filter sizes of our choosing to 
sequentially separate cells by size.  Based on proliferation, CFU and differentiation 
measurements, we were able to enrich for early progenitors in MSCs as shown by their enhanced 
ability to proliferate and differentiate.  Enrichment based on cell size may therefore be a 
mechanism by which to diminish heterogeneity and enhance biological function in MSCs.  
Further, separation by cell size will allow us to better understand the molecular signature 
associated with the small cell phenotype.  Future work using global gene expression analyses on 
the small and large cell subpopulations may allow for the identification of novel biomarkers that 
have yet to be discovered in MSCs.   
In Chapter 5, we addressed the immunosuppressive potential of MSCs from different cell 
lines and passages using a novel in vitro model system.  This approach is ideal in that we use 
clonal T cells specific for known peptide antigens, which reduces variability typically seen in 
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traditional polyclonal mixed lymphocyte reaction assays.  In doing so, using endpoints assessing 
changes in gene expression of Tbet and GATA3, expression of activation markers by PCR, and 
cytokine secretion, we determined that our model system successfully assesses 
immunosuppression by MSCs.  Further, our data suggests that there may be donor and passage 
differences in immunosuppressive potential of donors used here.  Future work will correlate 
these in vitro assay outcomes with an in vivo model system to better correlate and predict the role 
of donor variability and passaging in immunosuppressive capacity.   
Overall, we have extensively characterized MSC cell lines derived from eight human 
donors using both existing and novel quantifiable endpoints.  Interestingly, it appears as though 
all endpoints are not necessarily correlative, and that individual in vitro bioassay outcomes are 
donor and passage specific.  In other words, for example, proliferative potential does not 
necessarily predict the ability to undergo adipogenic or osteogenic differentiation, nor the ability 
of MSCs to immunosuppress.  Therefore, identification of biomarkers that are more predictive of 
in vitro and in vivo outcomes will certainly benefit the field.   A collective effort to further 
improve characterization of MSCs is currently being pursued at the FDA through the use of 
proteomics, and genetic and epigenetic-based discovery tools, which will help identify novel 
biomarkers that may better identify the MSCs used in this study.  An improved understanding of 
the MSC phenotype and more quantitative bioassays will aid in the discovery of novel 
biomarkers that may improve characterization and clinical outcome using MSCs. 
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APPENDIX A 
CHANGES IN GENE EXPRESSION FOLLOWING TRILINEAGE 
DIFFERENTIATION – A CELL LINE COMPARISON 
Changes in gene expression following adipogenic, osteogenic, and chondrogenic differentiation 
were reported in section 3.3.4.  Here, we report the same data, however compiled onto one graph 
to better visualize cell line differences in response to differentiation induction. 
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A.1 ADIPOGENESIS 
 
Figure A-1-1.  Change in C/EBP expression following adipogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed 
for expression of C/EBP by qRT-PCR.  Data is expressed as mean ± standard deviation.  
 
 
 
Figure A-1-2.  Change in FABP4 expression following adipogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed 
for expression of FABP4 by qRT-PCR.  Data is expressed as mean ± standard deviation.   
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Figure A-1-3.  Change in PPAR expression following adipogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in adipogenic differentiation medium, and assessed 
for expression of PPAR by qRT-PCR.  Data is expressed as mean ± standard deviation.   
A.2 OSTEOGENESIS 
 
Figure A-2-1.  Change in ALPL expression following osteogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed for 
expression of ALPL by qRT-PCR.  Data is expressed as mean ± standard deviation. 
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Figure A-2-2.  Change in RUNX2 expression following osteogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed 
for expression of RUNX2 by qRT-PCR.  Data is expressed as mean ± standard deviation. 
 
 
Figure A-2-3.  Change in SPP1 expression following osteogenic stimulation is donor- and passage-dependent.  
MSCs from all cell lines were cultured for 14 days in osteogenic differentiation medium, and assessed for 
expression of SPP1 by qRT-PCR.  Data is expressed as mean ± standard deviation.   
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A.3 CHONDROGENESIS 
 
Figure A-3-1.  Change in SOX9 expression following chondrogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 15 days in chondrogenic differentiation medium, and 
assessed for expression of SOX9 by qRT-PCR.  Data is expressed as mean ± standard deviation. 
 
 
 
Figure A-3-2.  Change in ACAN expression following chondrogenic stimulation is donor- and passage-
dependent.  MSCs from all cell lines were cultured for 15 days in chondrogenic differentiation medium, and 
assessed for expression of ACAN by qRT-PCR.  Data is expressed as mean ± standard deviation. 
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APPENDIX B 
MACRO SCRIPT TO QUANTIFY ADIPOGENESIS 
As described in Section 3.3.1.2, we quantified adipogenesis using Nile Red fluorescence 
measurements.  Following image acquisition, the percent Nile Red positive cells and nuclei 
counts were quantified using a macro written for Nikon Elements software.  The macro script 
used to quantify adipogenesis following automated microscopy is annotated in the table below 
(Table B-1). 
 
Table B-1.  Macro script and annotation utilized to quantify adipogenesis following automated microscopy. 
Elements Command Explanation 
ClearBinary(); Clears any previous binaries (thresholds) 
that have been applied to an image 
Zoom(100.0); Brings the image to 100% image 
resolution (this isn't needed for the program, 
however, it gives the user a better view of how 
the macro proceeds. 
ViewComponents("10"); Selects the first fluorescence channel (of a 
multichannel image) to be viewed only 
RegionalMaxima(16,3,0,1,0,7); This is an image processing function that 
looks at a pixel, or group of pixels, and compares 
this to the surrounding pixels to determine where 
the most intensity lies as a way of enhancing the 
peaks of an image relative to its immediate 
surroundings.  This is particularly useful for 
bringing out region-based contrast and can be 
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particularly useful for separation of features. 
DefineThresholdMCHOperation(1); 
DefineThresholdMCHChannel(0,20,255,0);
DefineThresholdMCHChannel(1,1,0,0); 
DefineThresholdProcessing(0,0,0); 
DefineThresholdRestrictionSize(0,0.00000
0,845.000000); 
DefineThresholdRestrictionCircularity(0,0.
000000,1.000000); 
ThresholdND(1,1,1); 
This group of commands defines the 
threshold with which a binary (mask) will be 
applied to the image.  This "all-in-one" function 
has the ability to define the intensity range that 
the binary will represent, and also can incorporate 
size and circularity restrictions should the user 
wish to implement them here. Although 
restrictions in this case were done subsequently. 
ViewComponents("10"); Selects the first fluorescence channel (of a 
multichannel image) to be viewed only 
FillHolesND(1,1,1); Once a binary has been applied, it may 
occur that one object (binary) can have areas 
within it, where there are no pixels selected.  In 
certain circumstances, the user may wish to fill in 
these holes as a step towards the final 
segmentation 
MorphoSeparateObjectsND(15,2,1,1,1); This function has many traditional names 
such as "watershed".  The basic function of this 
command is to cleave a bottleneck between 
objects that the user wishes to be separated.  The 
degree or "aggressiveness" of this function, is 
user selectable by selected the size of the cluster 
of pixels analyzed, as well as the number of 
iterations performed and can be experimented 
with to ensure the most accuracy of the function 
for the desired analysis. 
Restrictions("Area",1,1,100,99999999); Each binary can be made up of many 
individual objects.  This function allows the 
software to exclude or include these individual 
objects depending on their size.  It should be 
noted that once this command is executed, the 
objects are not yet discarded, however, the 
objects that do not make it into the specified size 
limits are "flagged" for further action. 
ScanObjectsND(1,1,1); Upon execution of this command, the 
software will look through the entire dataset and 
take a measurement of the size of each object that 
has been detected through segmentation at this 
point of the macro. 
Table B-1 (Continued)
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GenerateBinaryND(1,1,1); Allows the software to implement the 
previous "restrictions" command by deleting any 
objects that have been flagged for exclusion via a 
previous command. 
BinLayerStore("DAPI Cell Count","DAPI 
Count"); 
Takes the current binary and stores it for 
later use with the name specified. 
ViewComponents("01"); Selects the second fluorescence channel 
(of a multichannel image) to be viewed only. 
DefineThresholdMCHOperation(1); 
DefineThresholdMCHChannel(0,1,0,0); 
DefineThresholdMCHChannel(1,35,255,0);
DefineThresholdProcessing(0,0,0); 
DefineThresholdRestrictionSize(0,0.00000
0,999999999); 
DefineThresholdRestrictionCircularity(0,0.
000000,1.000000); 
ThresholdND(1,1,1); 
This group of commands defines the 
threshold with which a binary, or mask, will be 
applied to the image.  This "all-in-one" function 
has the ability to define the intensity range that 
the binary will represent, and also can incorporate 
size and circularity restrictions should the user 
wish to implement them here.  
ViewComponents("01"); Selects the second channel of a 
multichannel image for viewing (only). 
CloseBinaryND(1,4,1,1,1); A close function is a combination of a 
certain sequence of dialations and erosions.  Each 
object in the binary for example may be dialated 
by some number which will define the number of 
times a 1-pixel addition will be added to the outer 
perimeter of each object, followed by a erosion 
which will subtract 1 pixel (per each iteration) 
from the outer perimeter of each object.  The 
result is that if two objects come into contact with 
each other by dialation, the subsequent erosion 
will only erode the outer perimeter's pixels, thus 
maintaining the original size of the components 
and leaving the connection intact.  The purpose of 
this is normally, but not always, to connect 
objects that have been too aggressively separated 
by the macro so far and are more accurately 
defined as 1 object. 
FillHolesND(1,1,1); Once a binary has been applied, it may 
occur that one object (binary) can have areas 
within it, where there are no pixels selected.  In 
certain circumstances, the user may wish to fill in 
these holes as a step towards the final 
segmentation which is what this function does. 
ScanObjectsND(1,1,1); Upon execution of this command, the 
software will look through the entire dataset and 
take a measurement of the size of each object that 
Table B-1 (Continued)
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has been detected through segmentation at this 
point of the macro. 
Restrictions("Area",1,1,100,1.00e+008); Each binary image can be made up of 
many individual masks.  This function allows the 
software to exclude or include these individual 
pieces depending on their size.  It should be noted 
that once this command is executed, the objects 
are not yet completely deleted, however, the 
objects that do not make it into the specified size 
limits are "flagged" for further action. 
GenerateBinaryND(1,1,1); Allows the software to implement the 
previous "restrictions" command by deleting any 
objects that have been flagged for exclusion via a 
previous command. 
ConvexHullND(1,1,1); This function recognizes the shape of 
convex objects and fills the concavity to include 
this area in the mask.  This is particularly useful 
in cases where there is cytosolic, but not nuclear 
localization of a particular probe, yet one would 
like to include the nuclear signal of all cells 
expressing a cytosolic probe as a means of 
counting positive expression of cells relative to 
total number. 
BinLayerStore("Nile Red 
Positive","Threshold Nile Red"); 
Takes the current binary and stores it for 
later use with the name specified. 
BinLayerMergeND("DAPI-Nile Red 
Intersection", "DAPI Cell Count, Nile Red 
Positive", 2, 1, 1, 1); 
Merges two binary layers so that only the 
intersection of the two respective binary layers 
are now shown.  This newly created binary is its 
own binary layer which can be utilized for 
analysis. 
ScanObjectsND(1,1,1); Upon execution of this command, the 
software will look through the entire dataset and 
take a measurement of the size of each object that 
has been detected through segmentation at this 
point of the macro. 
Restrictions("Area",1,1,33.11,1.00e+008); Each binary image can be made up of 
many individual masks.  This function allows the 
software to exclude or include these individual 
pieces depending on their size.  It should be noted 
that once this command is executed, the objects 
are not yet completely deleted, however, the 
objects that do not make it into the specified size 
limits are "flagged" for further action. 
Table B-1 (Continued)
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GenerateBinaryND(1,1,1); Allows the software to implement the 
previous "restrictions" command by deleting any 
objects that have been flagged for exclusion via a 
previous command. 
ViewComponents("11"); Selects both the first and second channels 
of a multichannel image for viewing. 
OverlayTransparency(50); Sets the transparency of the mask which is 
overlaying the image 
BinLayerSelect("DAPI-Nile Red 
Intersection"); 
Selects a particular stored layer to be 
viewed 
 
Table B-1 (Continued)
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